<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">ZnCZGjfSbFKWBPF7SDrFKJj</article-id>
      <article-id pub-id-type="other">00021</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009001200021</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09300621</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009001200021</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigo de Revis&#227;o</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Efeito anti-inflamat&#243;rio do treinamento f&#237;sico na insufici&#234;ncia card&#237;aca: papel do TNF-&#945; e da IL-10</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Batista J&#250;nior</surname>
            <given-names>Miguel Luiz</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lopes</surname>
            <given-names>Renato Delascio</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Seelaender</surname>
            <given-names>Mar&#237;lia Cerqueira Leite</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lopes</surname>
            <given-names>Antonio Carlos</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Instituto de Ci&#234;ncias Biom&#233;dicas I </institution>
        <institution content-type="orgdiv2">Departamento de Medicina Interna</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff03">
        <addr-line>
          <named-content content-type="city">Durham</named-content>
          <named-content content-type="state">North Caroline</named-content>
        </addr-line>
        <institution content-type="orgname">Duke Clinical Research Institute</institution>
        <country country="">- USA</country>
      </aff>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Departamento de Medicina Interna </institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>12</month>
        <year>2009</year>
      </pub-date>
      <volume>93</volume>
      <issue>6</issue>
      <fpage>692</fpage>
      <lpage>700</lpage>
      <history>
        <date date-type="accepted">
          <day>15</day>
          <month>10</month>
          <year>2008</year>
        </date>
        <date date-type="rev-recd">
          <day>28</day>
          <month>09</month>
          <year>2009</year>
        </date>
        <date date-type="received">
          <day>25</day>
          <month>08</month>
          <year>2009</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Nos &#250;ltimos 50 anos, a compreens&#227;o sobre as altera&#231;&#245;es deteriorativas envolvidas na progress&#227;o da insufici&#234;ncia card&#237;aca (IC), descritas inicialmente como decorrentes de altera&#231;&#245;es na reten&#231;&#227;o de sais e fluidos, ou altera&#231;&#245;es nos par&#226;metros hemodin&#226;micos, mudou significatiamente. Recentemente, diversos estudos em pacientes com IC demonstraram n&#237;veis plasm&#225;ticos (ou no soro) alterados de citocinas pro-inflamat&#243;rias, tais como o fator &#945; de necrose tumoral (TNF-&#945;), as interleucinas 1, 6 e 18, e a cardiotropina-1, dentre outros marcadores inflamat&#243;rios. Essas altera&#231;&#245;es monstraram-se independentes da etiologia da IC, sugerindo uma via patog&#234;nica comum. Em reposta a esses novos achados, interven&#231;&#245;es no sentido de evitar e/ou reduzir essas altera&#231;&#245;es inflamat&#243;ria tem sido propostas. Os benef&#237;cios cardiovasculares, induzidos treinamento aer&#243;bio realizados em intensidades variando de leve a moderada, t&#234;m sido previamente relatados. Al&#233;m disso, tem-se demonstrado que o treinamento f&#237;sico (aer&#243;bio moderado) parece capaz de modular, na vig&#234;ncia de um quadro inflamat&#243;rio cr&#244;nico anormal, a express&#227;o elevada de citocinas pr&#243;-inflamat&#243;rias, mol&#233;culas de ades&#227;o sol&#250;veis, fatores quimioatratantes e estresse oxidativo. Tomados em conjunto, esses dados indicam um poss&#237;vel efeito anti-inflamat&#243;rio induzido pelo treinamento f&#237;sico. Dessa forma, esta revis&#227;o tem por objetivo abordar o treinamento f&#237;sico como uma alternativa n&#227;o farmacol&#243;gica adjuvante a ser administrada em alguns quadros patol&#243;gicos em que predominam as altera&#231;&#245;es cr&#244;nicas do TNF-&#945;, como na IC. Por sua vez, o "efeito anti-inflamat&#243;rio" induzido pelo treinamento f&#237;sico parece ser mediado principalmente pela IL-10.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Exerc&#237;cio</kwd>
        <kwd>insufici&#234;ncia card&#237;aca</kwd>
        <kwd>doen&#231;a da art&#233;ria coron&#225;ria</kwd>
        <kwd>interleucinas</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>05</day>
        <month>05</month>
        <year>2010</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>ARTIGO DE REVIS&#195;O</bold>
    </p>
    <p>
      <bold>Efeito anti-inflamat&#243;rio do treinamento f&#237;sico na insufici&#234;ncia card&#237;aca: papel do TNF-</bold>
      <bold>&#945; e da IL-10</bold>
    </p>
    <p>
      <bold>Miguel Luiz Batista J&#250;nior<sup>I</sup>; Renato Delascio Lopes<sup>II, III</sup>; Mar&#237;lia Cerqueira Leite Seelaender<sup>I</sup>; Antonio Carlos Lopes<sup>II</sup></bold>
    </p>
    <p><sup>I</sup>Grupo de Biologia Molecular da C&#233;lula - Instituto de Ci&#234;ncias Biom&#233;dicas I e Departamento de Medicina Interna - Universidade Federal de S&#227;o Paulo, SP - Brasil </p>
    <p><sup>II</sup>Departamento de Medicina Interna, Universidade Federal de S&#227;o Paulo, SP - Brasil </p>
    <p><sup>III</sup>Duke Clinical Research Institute, Durham- North Caroline - USA</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p>Nos &#250;ltimos 50 anos, a compreens&#227;o sobre as altera&#231;&#245;es deteriorativas envolvidas na progress&#227;o da insufici&#234;ncia card&#237;aca (IC), descritas inicialmente como decorrentes de altera&#231;&#245;es na reten&#231;&#227;o de sais e fluidos, ou altera&#231;&#245;es nos par&#226;metros hemodin&#226;micos, mudou significatiamente. Recentemente, diversos estudos em pacientes com IC demonstraram n&#237;veis plasm&#225;ticos (ou no soro) alterados de citocinas pro-inflamat&#243;rias, tais como o fator &#945; de necrose tumoral (TNF-&#945;), as interleucinas 1, 6 e 18, e a cardiotropina-1, dentre outros marcadores inflamat&#243;rios. Essas altera&#231;&#245;es monstraram-se independentes da etiologia da IC, sugerindo uma via patog&#234;nica comum. Em reposta a esses novos achados, interven&#231;&#245;es no sentido de evitar e/ou reduzir essas altera&#231;&#245;es inflamat&#243;ria tem sido propostas. </p>
    <p> Os benef&#237;cios cardiovasculares, induzidos treinamento aer&#243;bio realizados em intensidades variando de leve a moderada, t&#234;m sido previamente relatados. Al&#233;m disso, tem-se demonstrado que o treinamento f&#237;sico (aer&#243;bio moderado) parece capaz de modular, na vig&#234;ncia de um quadro inflamat&#243;rio cr&#244;nico anormal, a express&#227;o elevada de citocinas pr&#243;-inflamat&#243;rias, mol&#233;culas de ades&#227;o sol&#250;veis, fatores quimioatratantes e estresse oxidativo. Tomados em conjunto, esses dados indicam um poss&#237;vel efeito anti-inflamat&#243;rio induzido pelo treinamento f&#237;sico. </p>
    <p> Dessa forma, esta revis&#227;o tem por objetivo abordar o treinamento f&#237;sico como uma alternativa n&#227;o farmacol&#243;gica adjuvante a ser administrada em alguns quadros patol&#243;gicos em que predominam as altera&#231;&#245;es cr&#244;nicas do TNF-&#945;, como na IC. Por sua vez, o "efeito anti-inflamat&#243;rio" induzido pelo treinamento f&#237;sico parece ser mediado principalmente pela IL-10.</p>
    <p><bold>Palavras-chave: </bold> Exerc&#237;cio, insufici&#234;ncia card&#237;aca, doen&#231;a da art&#233;ria coron&#225;ria, interleucinas.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A insufici&#234;ncia card&#237;aca (IC) &#233; uma s&#237;ndrome cl&#237;nica de fisiopatologia complexa, que pode ser resultante de qualquer disfun&#231;&#227;o funcional ou estrutural que atinja o cora&#231;&#227;o, e consequentemente, comprometa a capacidade dos ventr&#237;culos de encherem e bombearem sangue satisfatoriamente<sup>1,2</sup>. As manifesta&#231;&#245;es cardinais da IC s&#227;o dispn&#233;ia e fadiga, as quais podem limitar a capacidade de realizar esfor&#231;o f&#237;sico (intoler&#226;ncia ao exerc&#237;cio f&#237;sico) e podem culminar em processos que conduzem &#224; congest&#227;o pulmonar sist&#234;mica e ao aumento da resist&#234;ncia vascular perif&#233;rica<sup>1,3,4</sup>. As principais causas de origem card&#237;aca da IC s&#227;o as doen&#231;as das art&#233;rias coron&#225;rias, a hipertens&#227;o, as cardiomiopatias dilatadas e as doen&#231;as das v&#225;lvulas card&#237;acas<sup>1,2</sup>.</p>
    <p>Atualmente, as altera&#231;&#245;es deteriorativas envolvidas na progress&#227;o da IC, as quais foram anteriormente compreendidas como decorrentes de altera&#231;&#245;es na reten&#231;&#227;o de sal e &#225;gua ou de altera&#231;&#245;es nos par&#226;metros hemodin&#226;micos, t&#234;m sido descritas como recorrentes de processos que culminam na ativa&#231;&#227;o inflamat&#243;ria local e sist&#234;mica<sup>5-9</sup>, evidenciadas pelo aumento na express&#227;o g&#234;nica e na produ&#231;&#227;o de citocinas pr&#243;-inflamat&#243;rias como: Fator &#945; de necrose tumoral (TNF-&#945;); interleucinas 1&#946; (IL-1&#946;), 6 (IL-6) e 18 (IL-18); cardiotropina-1; quimiocinas CC e CXC; dentre outros marcadores inflamat&#243;rios, no plasma, m&#250;sculo-esquel&#233;ticos e card&#237;acos, assim como em linf&#243;citos perif&#233;ricos em ratos e pacientes com IC. Esses mediadores inflamat&#243;rios podem, al&#233;m de contribuir para a fisiopatologia e progress&#227;o estrutural e funcional do m&#250;sculo card&#237;aco, atuar diretamente no aparecimento das manifesta&#231;&#245;es perif&#233;ricas da s&#237;ndrome da IC, principalmente nas altera&#231;&#245;es relacionadas &#224; diminui&#231;&#227;o da massa muscular e altera&#231;&#245;es funcionais<sup>10,11</sup>, dentre outras.</p>
    <p>Seguindo essa linha de racioc&#237;nio, Coats e cols.<sup>7</sup> propuseram uma hip&#243;tese intitulada "Hip&#243;tese muscular da IC", segundo a qual, as altera&#231;&#245;es degenerativas s&#227;o decorrentes de uma perfus&#227;o reduzida nos m&#250;sculos esquel&#233;ticos causada pelo baixo d&#233;bito card&#237;aco, resultando em uma hip&#243;xia tecidual. Se forem mantidas por um longo tempo, a hip&#243;xia tecidual e um consequente aumento na produ&#231;&#227;o de radicais livres passam a ser um potente est&#237;mulo para a produ&#231;&#227;o de citocinas pro-inflamat&#243;rias (TNF-&#945;, IL-1&#946; e IL-6), mediada pelo fator de transcri&#231;&#227;o nuclear &#186;B (&#186;NF-&#186;B), o qual iniciaria uma cascata de eventos que consiste na express&#227;o da &#243;xido n&#237;trico sintetase indut&#237;vel (iNOS), apoptose do m&#250;sculo esquel&#233;tico e perda de massa muscular<sup>5,11-13</sup>.</p>
    <p>Por conseguinte, apesar de nos &#250;ltimos anos a grande maioria dos estudos sobre IC terem enfocado as citocinas pr&#243;-inflamat&#243;rias, atualmente, as citocinas antiinflamat&#243;rias - em especial a IL-10 - t&#234;m ganhado destaque e podem ter um papel importante na fisiopatologia da IC<sup>14,15</sup>. Em pacientes com IC, uma diminui&#231;&#227;o na concentra&#231;&#227;o plasm&#225;tica de IL-10 tem sido relatada e correlacionada positivamente com uma piora na fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo<sup>16</sup>. Al&#233;m disso, em animais com IC induzida pelo IM, a utiliza&#231;&#227;o da rela&#231;&#227;o da produ&#231;&#227;o da IL-10 pelo TNF-&#945; (taxa IL-10/ TNF-&#945;) tem sido recentemente demonstrada como um indicador com maior precis&#227;o do grau de disfun&#231;&#227;o ventricular nessa condi&#231;&#227;o<sup>14,17</sup>.</p>
    <p>O treinamento f&#237;sico, realizado principalmente atrav&#233;s de exerc&#237;cios aer&#243;bios, tem sido considerado como a base de sustenta&#231;&#227;o dos programas de reabilita&#231;&#227;o card&#237;aca e uma importante forma de tratamento n&#227;o farmacol&#243;gico, atrav&#233;s do qual se pode alcan&#231;ar os objetivos estabelecidos para minimizar os fatores de risco que predisp&#245;em o indiv&#237;duo &#224;s doen&#231;as cardiovasculares<sup>18,19</sup>.</p>
    <p>Al&#233;m dos benef&#237;cios cardiovasculares, induzidos tanto pelas adapta&#231;&#245;es na fun&#231;&#227;o do cora&#231;&#227;o enquanto bomba, como nas adapta&#231;&#245;es perif&#233;ricas, o treinamento f&#237;sico parece capaz de modular, na vig&#234;ncia de um quadro inflamat&#243;rio cr&#244;nico anormal, a express&#227;o de citocinas pr&#243;-inflamatorias, mol&#233;culas de ades&#227;o sol&#250;veis e fatores quimioatratantes<sup>8,20</sup>. A utiliza&#231;&#227;o do treinamento aer&#243;bio em esteira ergom&#233;trica a 70% VO<sub>2pico</sub>, durante seis meses, foi capaz de atenuar a express&#227;o local aumentada de citocinas pr&#243;-inflamat&#243;rias (TNF-&#945;, IL-1&#946;, IL-6) no m&#250;sculo estriado esquel&#233;tico em pacientes com IC. Ainda no mesmo estudo, demonstrou-se que essa redu&#231;&#227;o foi associada &#224; redu&#231;&#227;o na express&#227;o do gene da isoforma indut&#237;vel da oxido n&#237;trico sintetase (&#237;ONS) e ao ac&#250;mulo intracelular de &#243;xido n&#237;trico (NO), sugerindo ent&#227;o que a utiliza&#231;&#227;o do treinamento f&#237;sico deva ser realizada n&#227;o apenas como uma forma de interven&#231;&#227;o que objetiva a melhora das capacidades f&#237;sicas (comprometidas ou n&#227;o pelo IC), mas como uma estrat&#233;gia terap&#234;utica com finalidade antiinflamat&#243;ria local.</p>
    <p>Nesse aspecto, estudos t&#234;m demonstrado altera&#231;&#245;es na concentra&#231;&#227;o plasm&#225;tica de IL-10 e IL-ra (receptor antagonista para IL-1) ap&#243;s o exerc&#237;cio f&#237;sico, condi&#231;&#227;o a qual pode contribuir ao <italic>milieu</italic> anti-inflamat&#243;rio, e dessa forma, ser um importante mediador dos efeitos anti-inflamat&#243;rios do treinamento f&#237;sico. A IL-10 pode atuar em diferentes tipos celulares e induz a supress&#227;o da resposta inflamat&#243;ria nos mais variados tipos celulares<sup>21</sup>. Al&#233;m disso, essa citocina tem sido postulada como a principal mol&#233;cula respons&#225;vel pelo "orquestramento" de rea&#231;&#245;es inflamat&#243;rias, em particular a inibi&#231;&#227;o das altera&#231;&#245;es mediadas pelo TNF-&#945;<sup>21,22</sup>.</p>
    <p>Por outro lado, apesar do aumento crescente de evid&#234;ncias indicando a rela&#231;&#227;o entre o efeito anti-inflamat&#243;rio do exerc&#237;cio f&#237;sico, bem como seu efeito protetor e/ou inibidor em v&#225;rios quadros patol&#243;gicos, os poss&#237;veis efeitos ao longo do tempo (treinamento) ainda n&#227;o est&#227;o bem caracterizados.</p>
    <p>Portanto, pode-se depreender que, apenas recentemente tem-se enfocado o poss&#237;vel efeito anti-inflamat&#243;rio do treinamento f&#237;sico sobre a produ&#231;&#227;o de citocinas pr&#243; (TNF-&#945;) e antiinflamat&#243;ria (IL-10) em pacientes com IC. Por outro lado, as adapta&#231;&#245;es oriundas do treinamento aer&#243;bio moderado (55% - 65% VO<sub>2pico</sub>) podem ter efeitos imunomoduladores, notadamente na produ&#231;&#227;o da IL-10, condi&#231;&#227;o que poderia ser ainda mais evidente em quadros patol&#243;gicos que apresentam, de maneira cr&#244;nica, um aumento na produ&#231;&#227;o desses marcadores inflamat&#243;rios. Al&#233;m disso, o aumento da atividade f&#237;sica &#233; cr&#237;tico no tratamento adjuvante de pacientes com IC, dependendo, naturalmente, da intensidade dessa redu&#231;&#227;o na gravidade da doen&#231;a.</p>
    <p>
      <bold>Papel do TNF-</bold>
      <bold>&#945; na progress&#227;o da IC</bold>
    </p>
    <p>Como descrito acima, as citocinas pr&#243;-inflamat&#243;rias, em especial o TNF-&#945;, bem como outros mediadores inflamat&#243;rios, como as quimiocinas, t&#234;m um papel de destaque em v&#225;rios n&#237;veis da IC, sendo que, no in&#237;cio, apesar de sua libera&#231;&#227;o ter fun&#231;&#227;o restauradora ou reparadora, quando mantidas ao longo do tempo podem ter um papel importante na modula&#231;&#227;o das altera&#231;&#245;es deteriorativas do quadro de IC<sup>23</sup>. Esses dados s&#227;o corroborados por outros provenientes de estudos em modelos em que se induziu experimentalmente n&#237;veis elevados de mediadores inflamat&#243;rios com o TNF-&#945; e o &#243;xido n&#237;trico, a fim de mimetizar algumas altera&#231;&#245;es cl&#237;nicas caracter&#237;sticas da IC, tais como disfun&#231;&#227;o progressiva do ventr&#237;culo esquerdo, edema pulmonar e cardiomiopatias<sup>24</sup>. Ainda, altera&#231;&#245;es detectadas nos n&#237;veis plasm&#225;ticos apresentam correla&#231;&#227;o com v&#225;rios marcadores de disfun&#231;&#245;es caracter&#237;sticas da IC, al&#233;m de serem marcadoras de progn&#243;stico e severidade da mesma<sup>25,26</sup>.</p>
    <p>Al&#233;m das altera&#231;&#245;es nos n&#237;veis plasm&#225;ticos, um estudo recente<sup>27</sup> demonstrou correla&#231;&#245;es positivas entre os n&#237;veis de TNF-&#945; no mi&#243;cito card&#237;aco e no n&#250;cleo paraventricular no hipot&#225;lamo em ratos com IC. Adicionalmente, essas altera&#231;&#245;es foram relacionadas &#224; maior excita&#231;&#227;o neuro-humoral na regi&#227;o cardiovascular cerebral<sup>28</sup>, e, juntamente com uma maior ativa&#231;&#227;o do sistema renina-angiotensina<sup>29</sup>, sugerem uma poss&#237;vel intera&#231;&#227;o entre esses sistemas (imune x renina-angiotensina) e modular altera&#231;&#245;es como reten&#231;&#227;o de s&#243;dio e &#225;gua e nos processos de remodela&#231;&#227;o card&#237;aca em ratos com IC.</p>
    <p>O TNF-&#945; foi descrito em 1975 e inicialmente foi nomeado como caquexina, devido a seu potente efeito citot&#243;xico contra c&#233;lulas tumorais<sup>23,25</sup>. &#201; um polipept&#237;dio trim&#233;rico (17 kDa), produzido principalmente por mon&#243;citos e macr&#243;fagos ativados, al&#233;m de outras c&#233;lulas, como: linf&#243;citos, fibroblastos, neutr&#243;filos, m&#250;sculo liso e mast&#243;citos<sup>23,30</sup>. Essa citocina pode atuar em quase todo o tipo de c&#233;lulas nucleadas, atrav&#233;s de dois tipos de receptores de membrana, tipo I (RTNF-I, p55) e tipo II (RTNF-II, p75), ou como mol&#233;cula sol&#250;vel, ambos ativos biologicamente<sup>8,23</sup>.</p>
    <p>Estudos anteriores demonstraram a presen&#231;a de ambos os tipos de receptores, tanto no m&#250;sculo esquel&#233;tico<sup>31</sup>, como no card&#237;aco<sup>8</sup>. Ap&#243;s a transla&#231;&#227;o, similarmente ao pr&#243;prio TNF-&#945;, ambos receptores s&#227;o inseridos na membrana celular. Na clivagem proteol&#237;tica, realizada por uma metaloproteinase conversora de TNF-&#945; (TACE), os RTNF, bem como o pr&#243;prio TNF-&#945;, s&#227;o liberados em sua forma sol&#250;vel. Dessa forma, os fragmentos dos dom&#237;nios extracelulares de ambos os receptores de TNF-&#945; (tipo I e II) podem ser liberados da membrana celular e quantificados em sua forma sol&#250;vel (RsTNF-I e RsTNF-II), na urina e no plasma, tendo sido apontados como reguladores da atividade biol&#243;gica desta citocina<sup>32</sup>.</p>
    <p>Em concentra&#231;&#245;es fisiol&#243;gicas, os RsTNF podem atuar como um "reservat&#243;rio de libera&#231;&#227;o lenta", aumentando dessa forma, a meia vida desta citocina<sup>23,33</sup>. Quando presente em concentra&#231;&#245;es elevadas, como em pacientes com IC severa (classe III e IV, NYHA), os RsTNF podem inibir o aumento patol&#243;gico da atividade do TNF-&#945;, atuando dessa forma como uma antimol&#233;cula de TNF-&#945;<sup>8</sup>.</p>
    <p>Em 1990, Lavine e cols.<sup>34</sup> observaram que pacientes com IC apresentaram n&#237;veis m&#233;dios aumentados dessa citocina (115 &#177; 25 x 9 &#177; 3 U/mL), quando comparados a indiv&#237;duos sem a doen&#231;a. Tamb&#233;m demonstraram que quanto maior o aumento, maior a tend&#234;ncia desses pacientes desenvolverem o quadro de caquexia card&#237;aca. Estudos recentes t&#234;m demonstrado concentra&#231;&#245;es elevadas de TNF-&#945; em indiv&#237;duos portadores de caquexia card&#237;aca, sendo essa citocina um importante preditor de perda de peso<sup>35</sup>.</p>
    <p>O TNF-&#945; pode ser o principal causador de uma s&#233;rie de dist&#250;rbios metab&#243;licos presentes em indiv&#237;duos com IC, tais como: elevada taxa metab&#243;lica<sup>25</sup>; diminui&#231;&#227;o do fluxo de sangue para tecidos perif&#233;ricos e disfun&#231;&#227;o endotelial<sup>7,36</sup>; ativa&#231;&#227;o da &#237;ONS<sup>11,37</sup>; e altera&#231;&#227;o no metabolismo das prote&#237;nas e dos lip&#237;deos<sup>38</sup>. Al&#233;m de seu conhecido efeito termog&#234;nico, concentra&#231;&#245;es elevadas dessas citocinas podem estar relacionadas &#224; eleva&#231;&#227;o nas concentra&#231;&#245;es plasm&#225;ticas de insulina, &#224;s anormalidades no metabolismo dos horm&#244;nios esteroidais, ao horm&#244;nio do crescimento<sup>39</sup>, &#224; disfun&#231;&#227;o do ventr&#237;culo esquerdo<sup>5</sup> e &#224; intoler&#226;ncia ao exerc&#237;cio<sup>3,7,40</sup>.</p>
    <p>No entanto, pouco se sabe em rela&#231;&#227;o aos mecanismos respons&#225;veis por induzir esse aumento na produ&#231;&#227;o de TNF-&#945;, e dessa forma, algumas hip&#243;teses t&#234;m sido propostas (<xref ref-type="fig" rid="f1">figura 1</xref>). Sabidamente, mon&#243;citos e macr&#243;fagos ativados s&#227;o a principal fonte de TNF-&#945;<sup>23</sup>, sendo que, um aumento na produ&#231;&#227;o de prostaglandina E<sub>2</sub>, observado em pacientes com IC, poderia estimular macr&#243;fagos a produzir TNF-&#945;<sup>38</sup>. Estudos anteriores<sup>41</sup> demonstraram que macr&#243;fagos da cavidade peritoneal, em ratos com IC induzida por IM, apresentam aumento na produ&#231;&#227;o de TNF-&#945;, entre outras citocinas pr&#243;-inflamat&#243;rias (IL-1&#946; e IL-6), quando estimulados com LPS.</p>
    <p content-type="asset">
      <fig id="f1">
        <graphic xlink:href="1678-4170-abc-93-06-0692-00021-gf01.jpg"/></fig>
    </p>
    <p>Por outro lado, evid&#234;ncias recentes t&#234;m sugerido que na IC, o TNF-&#945; estaria alterado independentemente do quadro inflamat&#243;rio e da causa da doen&#231;a, sugerindo que o aumento dessa citocina esteja mais associado &#224; presen&#231;a das limita&#231;&#245;es impostas pela IC, ao inv&#233;s de ser ela a causadora desse quadro<sup>6,42</sup>. Dessa forma, na IC, os mecanismos moduladores da produ&#231;&#227;o de TNF-&#945; s&#227;o pouco compreendidos, e, por outro lado, essa citocina parece ter um papel complexo sendo um "elo" de comunica&#231;&#227;o entre v&#225;rios sistemas regulat&#243;rios<sup>5,38</sup>.</p>
    <p>
      <bold>Papel do IL-10 na progress&#227;o da IC</bold>
    </p>
    <p>Devido ao grande n&#250;mero de estudos que relacionaram o papel das citocinas pr&#243;-inflamat&#243;rias com a patog&#234;nese e progress&#227;o da IC, consequentemente a essa, tem sido especulada a possibilidade de interven&#231;&#245;es com a manipula&#231;&#227;o de citocinas antiinflamat&#243;rias como adjuvantes nas terapias em pacientes com IC. Por outro lado, apesar desse potencial terap&#234;utico, apenas recentemente tem-se enfocado o papel de IL-10 na IC<sup>14,43</sup>.</p>
    <p>A interleucina 10 (IL-10) &#233; um polipept&#237;dio homodim&#233;rico de 17 kDa, que foi inicialmente descrito como um fator produzido por linf&#243;citos T auxiliadores (tipo 2) com propriedades inibit&#243;rias em clones de linf&#243;citos T auxiliadores (tipo 1), notadamente na resposta proliferativa e na produ&#231;&#227;o de citocinas<sup>21</sup>. Essa citocina &#233; produzida por uma s&#233;rie de diferentes tipos celulares, em especial as c&#233;lulas inflamat&#243;rias como macr&#243;fagos e linf&#243;citos T, onde &#233; o principal inibidor da s&#237;ntese de citocinas e da atividade funcional de macr&#243;fagos, bem como inibe a produ&#231;&#227;o, tanto das citocinas pr&#243;-inflamatorias, como das metaloproteinases da matriz extracelular<sup>8,21</sup>.</p>
    <p>Sua atividade biol&#243;gica &#233; mediada atrav&#233;s se seu receptor de membrana (IL-10R), o qual pertence ao subgrupo de receptores similares ao interferon (INF), da fam&#237;lia dos receptores de citocinas classe II<sup>21,22</sup>. Dessa forma, a IL-10 pode inibir a produ&#231;&#227;o de v&#225;rias citocinas, tais como TNF-&#945;, IL-1&#946; e IL-6, em uma variedade de tipos celulares, al&#233;m de se automodular<sup>15,21</sup>. Tamb&#233;m inibe a gera&#231;&#227;o de esp&#233;cies reativas do oxig&#234;nio (intermedi&#225;rios) e aumenta a libera&#231;&#227;o dos receptores RsTNF, os quais podem antagonizar os efeitos do TNF-&#945;<sup>44</sup>. Al&#233;m disso, estudos t&#234;m demonstrado que a IL-10 tem sua produ&#231;&#227;o aumentada em processos inflamat&#243;rios, como na anemia e na artrite reumat&#243;ide, al&#233;m da IC, exercendo uma fun&#231;&#227;o predominantemente imunomoduladora nessas condi&#231;&#245;es<sup>15</sup>.</p>
    <p>Bolger e cols.<sup>45</sup> demonstraram que a IL-10 inibe a secre&#231;&#227;o de TNF-&#945; em c&#233;lulas mononucleares do sangue perif&#233;rico isolado (<italic>ex vivo</italic>) de pacientes com IC (classe funcional III, NYHA). Em outro estado inflamat&#243;rio cr&#244;nico - como a aterosclerose - em camundongos (C57BL/6J, <italic>knockout</italic> para IL-10) a IL-10 tamb&#233;m tem sido descrita por suas propriedades protetoras (antiinflamat&#243;ria) em retardar a progress&#227;o da doen&#231;a, uma vez que altos n&#237;veis de IL-10 foram associados com a diminui&#231;&#227;o de apoptose e da express&#227;o de mRNA da &#237;ONS-1 em c&#233;lulas endoteliais, macr&#243;fagos e linf&#243;citos T desses animais<sup>46</sup>.</p>
    <p>Como foi bem caracterizado acima, a IL-10 atua predominantemente de maneira antiinflamat&#243;ria e modulat&#243;ria na resposta inflamat&#243;ria, condi&#231;&#227;o que parece ser ainda mais evidente em condi&#231;&#245;es (doen&#231;as) inflamat&#243;rias cr&#244;nicas, principalmente naquelas em que o TNF-&#945; parece atuar de maneira significativa (ex.: artrite reumat&#243;ide, esclerose m&#250;ltipla, doen&#231;a inflamat&#243;ria do trato digest&#243;rio, IC, dentre outras)<sup>45,47,48</sup>. Nesse sentido, o estudo de Gullestand e cols.<sup>43</sup> demonstrou que a infus&#227;o intravenosa de imunoglobulina - terapia utilizada em doen&#231;as mediadas pelo sistema imune, tais como s&#237;ndrome de Kawasaki, dematomiosite e esclerose m&#250;ltipla - em pacientes com IC (cardiomiopatia dilatada e doen&#231;a isqu&#234;mica do mioc&#225;rdio) aumentou os n&#237;veis de IL-10. Al&#233;m disso, esse aumento apresentou uma correla&#231;&#227;o positiva com a melhora na fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo em pacientes com IC, assim como em animais com IC induzida por IM. A rela&#231;&#227;o da produ&#231;&#227;o da IL-10 pelo TNF-&#945; (taxa IL-10/ TNF-&#945;) no ventr&#237;culo esquerdo demonstrou ser um indicador ainda mais preciso do grau de disfun&#231;&#227;o ventricular nessa condi&#231;&#227;o<sup>48</sup>.</p>
    <p>Recentemente, o estudo de Yu e cols.<sup>49</sup>, demonstrou que manifesta&#231;&#245;es perif&#233;ricas de IC induzida por IM em ratos, podem ser atenuadas pela redu&#231;&#227;o da intensidade da resposta inflamat&#243;ria/imune no c&#233;rebro. Nesses animais, a altera&#231;&#227;o no balan&#231;o de citocinas pr&#243; e antiinflamat&#243;rias induzidas pela administra&#231;&#227;o de um vetor adenoviral codificador do gene para IL-10 humano, obteve efeitos "ben&#233;ficos" nos &#237;ndices de severidade da IC, tais como melhora na fun&#231;&#227;o do ventr&#237;culo esquerdo e diminui&#231;&#227;o dos n&#237;veis de noradrenalina plasm&#225;tica, al&#233;m de menor proemin&#234;ncia na remodelagem do ventr&#237;culo direito e na congest&#227;o vascular pulmonar. Outro estudo, o qual administrou <italic>in vivo</italic> a rhIL-10, demonstrou o mesmo efeito<sup>45</sup>. Ainda nesse aspecto, Yamaoka e cols.<sup>15</sup> demonstraram que leuc&#243;citos mononucleares coletados de pacientes com IC (classe funcional II-IV, NYHA) apresentaram aumento dos receptores de IL-10 na membrana celular destas.</p>
    <p>Tomados em conjunto, esses estudos sugerem um papel de suma import&#226;ncia da IL-10 na fisiopatologia da IC, principalmente devido ao seu efeito modulador da s&#237;ntese e secre&#231;&#227;o do TNF-&#945;. Dessa forma, essa citocina vem ganhando um papel de destaque como possibilidade terap&#234;utica. Ainda nesse aspecto, a taxa IL-10/ TNF-&#945; pode ter um papel aditivo na avalia&#231;&#227;o da deteriora&#231;&#227;o e progress&#227;o do quadro da IC, e, por outro lado, mais estudos s&#227;o necess&#225;rios para a compreens&#227;o dos mecanismos moleculares que modulam os eventos supracitados.</p>
    <p>
      <bold>Efeito do treinamento aer&#243;bio nas citocinas pr&#243;-inflamat&#243;rias na IC</bold>
    </p>
    <p>&#201; bem caracterizado atualmente que o treinamento f&#237;sico est&#225; diretamente associado &#225; melhora funcional das capacidades f&#237;sicas condicionais, como no VO<sub>2pico</sub>, na fun&#231;&#227;o endotelial e consequentemente, na qualidade de vida em pacientes com IC<sup>11,50-52</sup>. Outras vari&#225;veis associadas a um pior progn&#243;stico, tais como melhora na atividade simp&#225;tica e neuro-hormonal e na hipoxia perif&#233;rica, tamb&#233;m t&#234;m sido relatadas como moduladas positivamente pelo treinamento f&#237;sico<sup>53</sup>. Outro aspecto ainda a se destacar &#233; o efeito direto na redu&#231;&#227;o na frequ&#234;ncia card&#237;aca subm&#225;xima (durante o exerc&#237;cio f&#237;sico) e em repouso<sup>50</sup>. Consequentemente, o treinamento f&#237;sico tem sido recomendado por diretrizes m&#233;dicas<sup>1,18</sup> como um componente terap&#234;utico em programas de reabilita&#231;&#227;o para pacientes com IC controlada.</p>
    <p>Al&#233;m dos benef&#237;cios j&#225; mencionados, recentemente, Adamapoulus e cols.<sup>54</sup> demonstraram uma redu&#231;&#227;o na concentra&#231;&#227;o plasm&#225;tica de marcadores inflamat&#243;rios perif&#233;ricos (mol&#233;cula sol&#250;vel de ades&#227;o celular-1, mol&#233;cula sol&#250;vel de c&#233;lula vascular-1 e prote&#237;na quimioatratante para macr&#243;fagos-1) ap&#243;s 12 semanas de treinamento aer&#243;bio em cicloerg&#244;metro (70-80% FC<sub>max</sub>), cinco vezes por semana durante uma hora por dia, em pacientes com IC moderada a severa (NYHA, classe funcional II - III), sugerindo uma correla&#231;&#227;o entre a melhora na toler&#226;ncia ao exerc&#237;cio e a atenua&#231;&#227;o do processo inflamat&#243;rio, devido a uma poss&#237;vel revers&#227;o dos efeitos delet&#233;rios causados pela disfun&#231;&#227;o endotelial apresentada no quadro de IC. Nesse sentido, Batista e cols.<sup>20</sup> demonstraram em ratos Wistar com IC induzida por infarto agudo do mioc&#225;rdio, ap&#243;s o emprego de um programa de treinamento aer&#243;bio moderado (corrida em esteira) com dura&#231;&#227;o de 10 semanas, a revers&#227;o de algums par&#226;metros inflamat&#243;rios em macr&#243;fagos peritoneais e linfonodos mesent&#233;ricos, atingindo valores pr&#243;ximos aos encontrados nos grupos controles. No entanto, a evid&#234;ncia da correla&#231;&#227;o significativa n&#227;o pode estabelecer uma rela&#231;&#227;o de causa-efeito, e outros mecanismos t&#234;m sido propostos para explicar os efeitos "ben&#233;ficos" mediados pelo treinamento f&#237;sico em indiv&#237;duos portadores de IC.</p>
    <p>A redu&#231;&#227;o na concentra&#231;&#227;o plasm&#225;tica de TNF-&#945;, IL-6 e seus respectivos receptores na forma sol&#250;vel tamb&#233;m t&#234;m sido demonstrada em indiv&#237;duos com IC submetidos a um programa de treinamento aer&#243;bio<sup>55</sup>, sugerindo uma atenua&#231;&#227;o no quadro inflamat&#243;rio cr&#244;nico, mediada por uma regula&#231;&#227;o na resposta inflamat&#243;ria perif&#233;rica<sup>56,57</sup>. No entanto, apesar de caracterizado o efeito restaurador e/ou antiinfalamario do exercicio nessas condi&#231;&#245;es, pouco se sabe a respeito dos poss&#237;veis mecanismos pelos quais o treinamento aer&#243;bio pode modular esse processo<sup>57</sup>.</p>
    <p>Seguindo essa linha de racioc&#237;nio, Gielen e cols.<sup>58</sup> publicaram o primeiro estudo que demonstrou o aumento na express&#227;o local de citocinas pr&#243;-inflamat&#243;rias, em amostras provenientes de biopsia do m&#250;sculo esquel&#233;tico em indiv&#237;duos com IC. Por outro lado, esse aumento n&#227;o foi demonstrado quando o par&#226;metro avaliado foi a concentra&#231;&#227;o plasm&#225;tica dessas citocinas e, dessa forma, tem-se especulado que a inflama&#231;&#227;o local precederia as altera&#231;&#245;es plasm&#225;ticas detectadas. Ainda nesse estudo, a utiliza&#231;&#227;o do treinamento aer&#243;bio em esteira ergom&#233;trica a 70% VO<sub>2pico</sub>, durante seis meses, foi capaz de atenuar essa express&#227;o local aumentada, um vez que demonstrou que essa redu&#231;&#227;o foi associada &#224; redu&#231;&#227;o na express&#227;o do gene da &#237;ONS e ao ac&#250;mulo intracelular de NO, sugerindo ent&#227;o que a utiliza&#231;&#227;o do treinamento f&#237;sico deve acontecer n&#227;o apenas como uma forma de interven&#231;&#227;o que objetiva a melhora das capacidades f&#237;sicas (comprometidas ou n&#227;o pelo IC), mas como uma estrat&#233;gia terap&#234;utica com finalidade antiinflamat&#243;ria local.</p>
    <p>Mais recentemente, o mesmo grupo de autores demonstrou que o efeito anti-inflamat&#243;rio induzido pelo treinamento aer&#243;bio na express&#227;o e produ&#231;&#227;o das citocinas (TNF-&#945;, IL-1&#946;, IL-6) e da &#237;ONS, os quais foram correlacionados &#224; melhora na atividade m&#225;xima da enzima citocromo <italic>c</italic> oxidase (COX) e no VO<sub>2pico</sub> , sugere que a melhora nos par&#226;metros inflamat&#243;rios ocorreram em fun&#231;&#227;o de uma melhora no metabolismo oxidativo do m&#250;sculo esquel&#233;tico em pacientes com IC<sup>11</sup>.</p>
    <p>A redu&#231;&#227;o na concentra&#231;&#227;o plasm&#225;tica de TNF-&#945;, IL-6 e seus respectivos receptores na forma sol&#250;vel tamb&#233;m t&#234;m sido demonstrada em indiv&#237;duos com IC submetidos a um programa de treinamento aer&#243;bio<sup>55</sup>, sugerindo uma atenua&#231;&#227;o no quadro inflamat&#243;rio cr&#244;nico, mediada por uma regula&#231;&#227;o na resposta inflamat&#243;ria perif&#233;rica<sup>54,55</sup>. Da mesma forma, a utiliza&#231;&#227;o de um programa de quatro meses de treinamento f&#237;sico com exerc&#237;cios aer&#243;bios em cicloerg&#244;metro (90% liminar anaer&#243;bico-I), tr&#234;s vezes por semana, durante 20 minutos, em conjunto com exerc&#237;cios resistidos (50% RM e nove exerc&#237;cios por sess&#227;o), durante 30 minutos, apresentou uma redu&#231;&#227;o na concentra&#231;&#227;o de sTNFR I e II em pacientes com IC, sugerindo um poss&#237;vel efeito dos exerc&#237;cios aer&#243;bios utilizados simultaneamente aos resistidos na atenua&#231;&#227;o do quadro inflamat&#243;rio<sup>56</sup>.</p>
    <p>Nessa condi&#231;&#227;o, as evid&#234;ncias cient&#237;ficas acumuladas recentemente sugerem que mediadores inflamat&#243;rios, como as citocinas pr&#243;-inflamat&#243;rias, t&#234;m um papel importante, tanto na patog&#234;nese, quanto no desenvolvimento da s&#237;ndrome da IC. Dessa forma, programas de treinamento f&#237;sico moderado, com dura&#231;&#227;o de tr&#234;s a seis meses, tr&#234;s a cinco sess&#245;es por semana, durante uma hora, al&#233;m de exercerem um efeito positivo nas vari&#225;veis cardiocirculat&#243;rias, j&#225; bem estabelecido na literatura, atuariam como um importante imunomodulador positivo, revertendo, mesmo que de maneira parcial, as altera&#231;&#245;es inflamat&#243;rias decorrentes do quadro de IC, refor&#231;ando seu papel de interven&#231;&#227;o n&#227;o-farmacol&#243;gica.</p>
    <p>
      <bold>Papel do treinamento f&#237;sico como estrat&#233;gia antiinflamat&#243;ria</bold>
    </p>
    <p>Nos &#250;ltimos anos, v&#225;rios estudos t&#234;m proposto que o exerc&#237;cio f&#237;sico (sess&#227;o aguda) exerce uma a&#231;&#227;o antiinflamat&#243;ria, notadamente logo ap&#243;s a realiza&#231;&#227;o deste, e por sua vez, a principal citocina envolvida nessa modula&#231;&#227;o &#233; a IL-6<sup>59,60</sup>. Esse efeito anti-inflamat&#243;rio &#233; caracterizado pelo aumento plasm&#225;tico, subsequente, das citocinas IL-10, ILra e dos receptores sol&#250;veis do TNF I e II, induzidas pela IL-6, ap&#243;s uma sess&#227;o de exerc&#237;cio f&#237;sico<sup>60</sup>. Ainda, esse efeito tem demonstrado ser mais evidente em alguns quadros patol&#243;gicos, como aterosclerose, diabetes tipo II, obesidade e IC, principalmente aqueles que apresentam o quadro caracterizado como inflama&#231;&#227;o sist&#234;mica cr&#244;nica de baixa intensidade (do ingl&#234;s <italic>low grade chronic inflammation</italic>), condi&#231;&#227;o caracterizada pelo aumento sist&#234;mico de duas a tr&#234;s vezes nos n&#237;veis de citocinas pr&#243;-inflamat&#243;rias e prote&#237;na C reativa<sup>61</sup> (<xref ref-type="fig" rid="f2">figura 2</xref>).</p>
    <p content-type="asset">
      <fig id="f2">
        <graphic xlink:href="1678-4170-abc-93-06-0692-00021-gf02.jpg"/></fig>
    </p>
    <p>Al&#233;m disso, esse perfil de produ&#231;&#227;o das citocinas que ocorre durante e imediatamente ap&#243;s a realiza&#231;&#227;o do exerc&#237;cio f&#237;sico &#233; dependente de v&#225;rios fatores, tais como popula&#231;&#227;o (sedent&#225;rios, presen&#231;a ou n&#227;o de doen&#231;as, etc.); intensidade ou dura&#231;&#227;o do exerc&#237;cio f&#237;sico; disponibilidade de glicose; e tempo de coleta das amostras<sup>62</sup>.</p>
    <p>Dada essa condi&#231;&#227;o, a hip&#243;tese que tem sido proposta &#233; que a pr&#225;tica regular de exerc&#237;cio f&#237;sico, organizado em um programa de treinamento, exerce um efeito anti-inflamat&#243;rio induzido pelas v&#225;rias sess&#245;es agudas, o qual conduziria a uma prote&#231;&#227;o contra situa&#231;&#245;es inflamat&#243;rias cr&#244;nicas, notadamente pela redu&#231;&#227;o dos n&#237;veis de citocinas pr&#243;-inflamat&#243;rias e prote&#237;na C reativa<sup>60,63</sup>. Apesar da evidente correla&#231;&#227;o, pouca informa&#231;&#227;o foi produzida at&#233; o momento a respeito dos poss&#237;veis mecanismos que culminam na rela&#231;&#227;o causa-efeito do treinamento f&#237;sico e na redu&#231;&#227;o desses marcadores<sup>59</sup>. Ainda nesses quadros, a origem dessa altera&#231;&#227;o sist&#234;mica n&#227;o est&#225; bem caracterizada, por&#233;m, tem sido proposto que o tecido adiposo branco<sup>60</sup> e as c&#233;lulas mononucleares do sangue perif&#233;rico (em especial os linf&#243;citos) podem ser a principal fonte dessas citocinas<sup>59,63</sup>.</p>
    <p>Para avaliar esse poss&#237;vel efeito anti-inflamat&#243;rio, Starkie e cols.<sup>64</sup> demonstraram, em um modelo experimental de inflama&#231;&#227;o sist&#234;mica de baixa intensidade, o qual foi induzido atrav&#233;s da administra&#231;&#227;o venosa de endotoxina (<italic>Escherichia coli</italic>) em indiv&#237;duos saud&#225;veis, ap&#243;s tr&#234;s horas da realiza&#231;&#227;o de uma sess&#227;o de exerc&#237;cio aer&#243;bio em cicloerg&#244;metro (75 % do VO<sub>2pico</sub>), uma redu&#231;&#227;o nos n&#237;veis de TNF-&#945; induzido pelo modelo experimental. Esse mesmo efeito supressor induzido pelo exerc&#237;cio f&#237;sico, tamb&#233;m foi demonstrado em camundongos <italic>knockout</italic> para os receptores de TNF-&#945; tipo I e II, restaurando os n&#237;veis aumentados de TNF-&#945;<sup>65</sup>. Por&#233;m, os poss&#237;veis mecanismos moduladores deste efeito "ben&#233;fico" n&#227;o est&#227;o estabelecidos.</p>
    <p>
      <bold>Poss&#237;veis mecanismos envolvidos na resposta antiinflamat&#243;ria ap&#243;s o exerc&#237;cio f&#237;sico</bold>
    </p>
    <p>Apesar de nos &#250;ltimos anos ter-se evidenciado a import&#226;ncia dos mediadores pr&#243;-inflamat&#243;rios na patog&#234;nese da IC, apenas recentemente observou-se que esta n&#227;o foi acompanhada por um aumento correspondente nas citocinas antiinflamat&#243;rias, tais como a IL-10, e do fator de transforma&#231;&#227;o do crescimento (TGF), resultando em um desequil&#237;brio no balan&#231;o de citocinas (pr&#243; vs antiinflamat&#243;rias).</p>
    <p>A terap&#234;utica farmacol&#243;gica convencionalmente utilizada na IC com impacto em mortalidade (ex: &#946;-bloqueadores, inibidores da enzima conversora de angiotensina e espironolactona) tem demonstrado efeito discreto na redu&#231;&#227;o de marcadores inflamat&#243;rios nesses pacientes, e dessa forma, a terapia imunomodulat&#243;ria tem sido proposta e testada em combina&#231;&#227;o ao tratamento convencional como uma op&#231;&#227;o adjuvante<sup>66</sup>. Dada essa condi&#231;&#227;o, a terap&#234;utica adjuvante (ex: pentoxifilina, imunoglobulina intravenosa, talidomina, infliximab e as estatinas) tem demonstrado resultados promissores em pequenos estudos, por&#233;m, apenas no que se refere a desfechos de menor relev&#226;ncia cl&#237;nica, como por exemplo, a melhora de perfil bioqu&#237;mico<sup>66</sup>. Tradicionalmente, pacientes com IC s&#227;o exclu&#237;dos de estudos em que se testam efeitos de estatinas em eventos cl&#237;nicos. No entanto, recentemente, um estudo<sup>67</sup> avaliou o efeito da estatina (rosuvastatina) em pacientes com mais de 60 anos de idade e com insufici&#234;ncia card&#237;aca sist&#243;lica moderada a severa. Nesse estudo, o uso de 10mg/dia de rosuvastatina teve um efeito estatisticamente significante na redu&#231;&#227;o dos n&#237;veis de LDL-colesterol e marcadores inflamat&#243;rios como a prote&#237;na C reativa.</p>
    <p>Nesse aspecto, como descrito acima, a utiliza&#231;&#227;o do treinamento f&#237;sico como terap&#234;utica adjuvante tem-se mostrado, al&#233;m de restaurador das fun&#231;&#245;es cardiovasculares ocorridas em decorr&#234;ncia da IC (que parece n&#227;o ocorrer nas terap&#234;uticas adjuvantes acima citadas), um importante agente imunomodulador. Por outro lado, apesar do aumento de evid&#234;ncias que demonstram a import&#226;ncia da IL-10, principalmente devido a sua a&#231;&#227;o antiinflamat&#243;ria, e at&#233; onde sabemos, poucos s&#227;o os estudos que avaliaram os poss&#237;veis efeitos do treinamento f&#237;sico em modular a produ&#231;&#227;o local de IL-10, a qual possui um papel importante no bala&#231;o pr&#243;/anti-inflamat&#243;rio, principalmente em condi&#231;&#245;es em que h&#225; um desequil&#237;brio nessa rela&#231;&#227;o.</p>
    <p>Dada essa condi&#231;&#227;o, a hip&#243;tese que tem sido proposta &#233; que a pr&#225;tica regular de exerc&#237;cio f&#237;sico, organizado em um programa de treinamento, exerce um efeito anti-inflamat&#243;rio induzido pelas v&#225;rias sess&#245;es agudas, o qual conduziria a uma prote&#231;&#227;o contra situa&#231;&#245;es inflamat&#243;rias cr&#244;nicas, notadamente pela redu&#231;&#227;o dos n&#237;veis de citocinas pr&#243;-inflamat&#243;rias e prote&#237;na C reativa<sup>60,63</sup>. Por&#233;m, os poss&#237;veis mecanismos moduladores desse efeito "ben&#233;fico" n&#227;o est&#227;o estabelecidos, e poderiam estar relacionados tanto &#224; melhora nas capacidades f&#237;sicas condicionais como ao efeito anti-inflamat&#243;rio direto.</p>
    <p>Como j&#225; foi descrito, a IL-10 modula processos inflamat&#243;rios atrav&#233;s da supress&#227;o da produ&#231;&#227;o de citocinas pr&#243;-inflamat&#243;rias, em especial o TNF-&#945;, o qual &#233; transcricionalmente modulado pelo sistema &#954;NF-&#954;B. Al&#233;m disso, um estudo recente demonstrou que, em ratos, o treinamento aer&#243;bio em esteira ergom&#233;trica aumenta a ativa&#231;&#227;o desse sistema, notadamente via redu&#231;&#227;o dos n&#237;veis de I&#954;B&#945; (prote&#237;na inibit&#243;ria do sistema NF-&#954;B) e aumento na fosforila&#231;&#227;o da IKK (enzima que degrada o complexo prot&#233;ico I&#954;B)<sup>68</sup>. Vale ainda destacar neste ponto que, apesar das evid&#234;ncias demonstrarem que a IL-10 inibe uma s&#233;rie de altera&#231;&#245;es mediadas pelo TNF-&#945;, principalmente aqueles que envolvem a ativa&#231;&#227;o do fator de trancri&#231;&#227;o NF-&#954;B, e que o treinamento aer&#243;bio aumenta a ativa&#231;&#227;o desse sistema, at&#233; o presente momento, nenhum desses estudos avaliou o efeito do treinamento em uma condi&#231;&#227;o em que haja a ativa&#231;&#227;o do sistema NF-&#954;B, tal qual a IC. Por outro lado, em pacientes com diabete tipo II, o programa de treinamento aer&#243;bio em bicicleta ergom&#233;trica (70% VO<sub>2pico</sub>, quatro vezes por semana, durante oito semanas) demonstrou um aumento nos n&#237;veis prot&#233;ico da I&#954;B&#945; e &#946; em ambos os indiv&#237;duos (diab&#233;ticos e controle da mesma idade) o qual foi seguido da redu&#231;&#227;o dos n&#237;veis prot&#233;icos do TNF-&#945;<sup>69</sup>. Assim, os prov&#225;veis mecanismos a respeito do poss&#237;vel efeito do treinamento f&#237;sico na IC, em modular a produ&#231;&#227;o de TNF-&#945; atrav&#233;s do aumento da IL-10 est&#225; demonstrado na <xref ref-type="fig" rid="f3">figura 3</xref>.</p>
    <p content-type="asset">
      <fig id="f3">
        <graphic xlink:href="1678-4170-abc-93-06-0692-00021-gf03.jpg"/></fig>
    </p>
    <p>
      <bold>Considera&#231;&#245;es Finais</bold>
    </p>
    <p>Dado o exposto, dados provenientes da literatura especializada corroboram a hip&#243;tese antiinflamat&#243;ria. Notadamente, a prote&#237;na IL-10 parece ser afetada pelo treinamento f&#237;sico (principalmente aer&#243;bio), podendo atuar como um importante "gatilho" na atenua&#231;&#227;o e/ou modula&#231;&#227;o da resposta inflamat&#243;ria na IC. Ainda, al&#233;m do aumento local na produ&#231;&#227;o de IL-10, induzido pelo treinamento f&#237;sico, esse efeito poderia ter impacto sist&#234;mico, reduzindo, ou at&#233; mesmo evitando o aumento nos n&#237;veis plasm&#225;ticos das citocinas pr&#243;-inflamat&#243;rias, condi&#231;&#227;o que, no caso da IC est&#225; relacionada &#224; maior severidade dessa doen&#231;a. Estudos avaliando o efeito do treinamento f&#237;sico controlado em desfechos cl&#237;nicos relevantes, como mortalidade em pacientes com IC, s&#227;o necess&#225;rios para que essa modalidade terap&#234;utica possa eventualmente ser incorporada a pr&#225;tica cl&#237;nica.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de tese de Doutorado de Miguel Luiz Batista J&#250;nior pelo Departamento de Biologia Celular e do Desenvolvimento do Instituto de Ci&#234;ncias Biom&#233;dicas - USP.</p>
    <p>
      <fn id="back" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Miguel Luiz Batista J&#250;nior </p>
        <p> Instituto de Ci&#234;ncias Biom&#233;dicas I, Universidade de S&#227;o Paulo </p>
        <p> Av. Lineu Prestes, 1524, sala 434, - Butant&#227; </p>
        <p> 05508-900, S&#227;o Paulo, SP, Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="migueljr@usp.br">migueljr@usp.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 25/08/08; revisado recebido em 28/09/08; aceito em 15/10/08.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Sociedade Brasileira    de Cardiologia. Revis&#227;o das II Diretrizes da Sociedade Brasileira de    Cardiologia para o diagn&#243;stico e tratamento da insufici&#234;ncia card&#237;aca.    Arq Bras Cardiol. 2002; 79: 1-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Revis&#227;o das II Diretrizes da Sociedade Brasileira de Cardiologia para o diagn&#243;stico e tratamento da insufici&#234;ncia card&#237;aca</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1</fpage>
          <lpage>30</lpage>
          <volume>79</volume>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Hunt SA, Abraham    WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline    update for the diagnosis and management of chronic heart failure in the adult:    A report of the American College of Cardiology/American Heart Association task    force on practice guidelines (Writing Committee to Update the 2001 Guidelines    for the Evaluation and Management of Heart Failure): Developed in collaboration    with the American College of Chest Physicians and the International Society    for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation.    2005; 112 (12): e154-235.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>e154</fpage>
          <lpage>235</lpage>
          <issue>12</issue>
          <volume>112</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hunt</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Abraham</surname>
              <given-names>WT</given-names>
            </name>
            <name>
              <surname>Chin</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Francis</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Ganiats</surname>
              <given-names>TG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Larsen AI, Lindal    S, Aukrust P, Toft I, Aarsland T, Dickstein K. Effect of exercise training on    skeletal muscle fibre characteristics in men with chronic heart failure. Correlation    between skeletal muscle alterations, cytokines and exercise capacity. Int J    Cardiol. 2002; 83 (1): 25-32.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of exercise training on skeletal muscle fibre characteristics in men with chronic heart failure: Correlation between skeletal muscle alterations, cytokines and exercise capacity</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>25</fpage>
          <lpage>32</lpage>
          <issue>1</issue>
          <volume>83</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Larsen</surname>
              <given-names>AI</given-names>
            </name>
            <name>
              <surname>Lindal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Aukrust</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Toft</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Aarsland</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Dickstein</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Guimar&#227;es    GV, Silva MSV, D'Avila VM, Ferreira SM, Silva CP, Bocchi EA. VO2 pico e inclina&#231;&#227;o    VE/VCO2 na era dos betabloqueadores na insufici&#234;ncia card&#237;aca:    uma experi&#234;ncia brasileira. Arq Bras Cardiol. 2008; 91: 42-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>VO2 pico e inclina&#231;&#227;o VE/VCO2 na era dos betabloqueadores na insufici&#234;ncia card&#237;aca: uma experi&#234;ncia brasileira</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>42</fpage>
          <lpage>8</lpage>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Guimar&#227;es</surname>
              <given-names>GV</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>MSV</given-names>
            </name>
            <name>
              <surname>D'Avila</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Paulus WJ. How    are cytokines activated in heart failure? Eur J Heart Fail. 1999; 1 (4): 309-12.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>How are cytokines activated in heart failure?</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>309</fpage>
          <lpage>12</lpage>
          <issue>4</issue>
          <volume>1</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Paulus</surname>
              <given-names>WJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Yndestad A,    Kristian Dam&#229;s J, &#216;ie E, Ueland T, Gullestad L, Alkrust P. Systemic    inflammation in heart failure - The whys and wherefores. Heart Fail Rev. 2006;    11 (1): 83-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Systemic inflammation in heart failure - The whys and wherefores</article-title>
          <source>Heart Fail Rev</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>83</fpage>
          <lpage>92</lpage>
          <issue>1</issue>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yndestad</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kristian Dam&#229;s</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>&#216;ie</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ueland</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gullestad</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Alkrust</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Coats A, Clark    A, Piepoli M, Volterrani M, Poole-Wilson PA. Symptoms and quality of lyfe in    heart failure: the muscle hypothesis. Br Heart J. 1994; 72 (2 Suppl): S36-39.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Symptoms and quality of lyfe in heart failure: the muscle hypothesis</article-title>
          <source>Br Heart J</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>S36</fpage>
          <lpage>39</lpage>
          <volume>72</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Coats</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Piepoli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Volterrani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Poole-Wilson</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Anker SD, von    Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart.    2004; 90 (4): 464-70.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Inflammatory mediators in chronic heart failure: an overview</article-title>
          <source>Heart</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>464</fpage>
          <lpage>70</lpage>
          <issue>4</issue>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Anker</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>von Haehling</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Candia AM, Villacorta    J&#250;nior H, Mesquita ET. Ativa&#231;&#227;o imune-inflamat&#243;ria    na insufici&#234;ncia card&#237;aca. Arq Bras Cardiol. 2007; 89: 201-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ativa&#231;&#227;o imune-inflamat&#243;ria na insufici&#234;ncia card&#237;aca</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>201</fpage>
          <lpage>8</lpage>
          <volume>89</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Candia</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Villacorta J&#250;nior</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mesquita</surname>
              <given-names>ET</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Toth MJ, Ades    PA, Tischler MD, Tracy RP, Lewinter MM. Immune activation is associated with    reduced skeletal muscle mass and physical function in chronic heart failure.    Int J Cardiol. 2006; 109 (2): 179-87.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Immune activation is associated with reduced skeletal muscle mass and physical function in chronic heart failure</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>179</fpage>
          <lpage>87</lpage>
          <issue>2</issue>
          <volume>109</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Toth</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Ades</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Tischler</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Tracy</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Lewinter</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Gielen S, Adams    V, Linke A, Erbs S, Mobius-Winkler S, Schubert A, et al. Exercise training in    chronic heart failure: correlation between reduced local inflammation and improved    oxidative capacity in the skeletal muscle. Eur J Cardiovasc Prev Rehabil. 2005;    12 (4): 393-400.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise training in chronic heart failure: correlation between reduced local inflammation and improved oxidative capacity in the skeletal muscle</article-title>
          <source>Eur J Cardiovasc Prev Rehabil</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>393</fpage>
          <lpage>400</lpage>
          <issue>4</issue>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gielen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Linke</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Erbs</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mobius-Winkler</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schubert</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Sp&#228;te    U, Schulze PC. Proinflammatory cytokines and skeletal muscle. Curr Opin Clin    Nutr Metab Care. 2004; 7: 265-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Proinflammatory cytokines and skeletal muscle</article-title>
          <source>Curr Opin Clin Nutr Metab Care</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>265</fpage>
          <lpage>9</lpage>
          <volume>7</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sp&#228;te</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Schulze</surname>
              <given-names>PC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Gielen S, Walther    C, Schuler G, Hambrecht R. Anti-inflammatory effects of physical exercise: a    new mechanism to explain the benefits of cardiac rehabilitation? J Cardiopulm    Rehab. 2005; 25 (6): 339-42.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anti-inflammatory effects of physical exercise: a new mechanism to explain the benefits of cardiac rehabilitation?</article-title>
          <source>J Cardiopulm Rehab</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>339</fpage>
          <lpage>42</lpage>
          <issue>6</issue>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gielen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Walther</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schuler</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hambrecht</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Stumpf C, Lehner    C, Yilmaz A, Daniel WG, Garlichs CD. Decrease of serum levels of the anti-inflammatory    cytokine interleukin-10 in patients with advanced chronic heart failure. Clin    Sci (Lond). 2003; 105 (1): 45-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure</article-title>
          <source>Clin Sci (Lond)</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>45</fpage>
          <lpage>50</lpage>
          <issue>1</issue>
          <volume>105</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Stumpf</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lehner</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Yilmaz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Daniel</surname>
              <given-names>WG</given-names>
            </name>
            <name>
              <surname>Garlichs</surname>
              <given-names>CD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Yamaoka M,    Yamaguchi S, Okuyama M, Tomoike H. Anti-inflammatory cytokine profile in human    heart failure: behavior of interleukin-10 in association with tumor necrosis    factor-alpha. Jpn Circ J. 1999; 63 (12): 951-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anti-inflammatory cytokine profile in human heart failure: behavior of interleukin-10 in association with tumor necrosis factor-alpha</article-title>
          <source>Jpn Circ J</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>951</fpage>
          <lpage>6</lpage>
          <issue>12</issue>
          <volume>63</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yamaoka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yamaguchi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Okuyama</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tomoike</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Waehre T, Halvorsen    B, Damas JK, Yndestad A, Brosstad F, Gullestad L, et al. Inflammatory imbalance    between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects    of IL-10. Eur J Clin Invest. 2002; 32 (11): 803-10.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Inflammatory imbalance between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects of IL-10</article-title>
          <source>Eur J Clin Invest</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>803</fpage>
          <lpage>10</lpage>
          <issue>11</issue>
          <volume>32</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Waehre</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Halvorsen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Damas</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Yndestad</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brosstad</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gullestad</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Kaur K, Sharma    A, Singal P. Significance of changes in TNF-{alpha} and IL-10 levels in the    progression of heart failure subsequent to myocardial infarction. Am J Physiol    Heart Circ Physiol. 2006; 291 (1): H106-113.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Significance of changes in TNF-{alpha} and IL-10 levels in the progression of heart failure subsequent to myocardial infarction</article-title>
          <source>Am J Physiol Heart Circ Physiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>H106</fpage>
          <lpage>113</lpage>
          <issue>1</issue>
          <volume>291</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kaur</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Singal</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Balady GJ,    Williams MA, Ades PA, Bittner V, Comoss P, Foody JM, et al. Core Components    of Cardiac Rehabilitation/Secondary Prevention Programs: 2007 Update: A Scientific    Statement From the American Heart Association Exercise, Cardiac Rehabilitation,    and Prevention Committee, the Council on Clinical Cardiology; the Councils on    Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical    Activity, and Metabolism; and the American Association of Cardiovascular and    Pulmonary Rehabilitation. Circulation. 2007; 115 (20): 2675-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Core Components of Cardiac Rehabilitation/Secondary Prevention Programs: 2007 Update: A Scientific Statement From the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation</article-title>
          <source>Circulation</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2675</fpage>
          <lpage>82</lpage>
          <issue>20</issue>
          <volume>115</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Balady</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Ades</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Bittner</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Comoss</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Foody</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Perk J, Veress    G. Cardiac rehabilitation: applying exercise physiology in clinical practice.    Eur J Appl Physiol. 2000; 83 (4): 457-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac rehabilitation: applying exercise physiology in clinical practice</article-title>
          <source>Eur J Appl Physiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>457</fpage>
          <lpage>62</lpage>
          <issue>4</issue>
          <volume>83</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Perk</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Veress</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Batista ML    Jr, Santos RVT, Oliveira EM, Seelaender MC, Costa Rosa LF. Endurance training    restores peritoneal macrophage function in post-MI congestive heart failure    rats. J Appl Physiol. 2007; 102 (5): 2033-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Endurance training restores peritoneal macrophage function in post-MI congestive heart failure rats</article-title>
          <source>J Appl Physiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2033</fpage>
          <lpage>9</lpage>
          <issue>5</issue>
          <volume>102</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Batista</surname>
              <given-names>ML Jr</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>RVT</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Seelaender</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Costa Rosa</surname>
              <given-names>LF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Malefyt R.    Interleukin-10. In: Mire-Sluis A, Thorpe R (eds.). Cytokines. 2nd ed. London:    Academic Press; 1999. p. 151-61.</mixed-citation>
        <element-citation publication-type="book">
          <source>Cytokines</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>151</fpage>
          <lpage>61</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Malefyt</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mire-Sluis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Thorpe</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Moore K, Malefyt    R, Coffman R, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu    Rev Immunol. 2001; 19 (1): 683-765.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Interleukin-10 and the interleukin-10 receptor</article-title>
          <source>Annu Rev Immunol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>683</fpage>
          <lpage>765</lpage>
          <issue>1</issue>
          <volume>19</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Moore</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Malefyt</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Coffman</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>O'Garra</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Beyaert R,    Fiers W. Tumor necrosis factor and lymphotoxin. In: Mire-Sluis A, Thorpe R,    (eds.). Cytokines. 2nd ed. London: Academic Press; 1999. p. 335-45.</mixed-citation>
        <element-citation publication-type="book">
          <source>Cytokines</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>335</fpage>
          <lpage>45</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Beyaert</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fiers</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Mire-Sluis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Thorpe</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Shan K, Kurrelmeyer    K, Seta Y, Wang F, Dibbs Z, Deswal A, et al. The role of cytokines in disease    progression in heart failure. Curr Opin Cardiol. 1997; 12 (3): 218-23.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The role of cytokines in disease progression in heart failure</article-title>
          <source>Curr Opin Cardiol</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>218</fpage>
          <lpage>23</lpage>
          <issue>3</issue>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shan</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kurrelmeyer</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Seta</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Dibbs</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Deswal</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Anker S, Steinborn    W, Strassburg S. Cardiac cachexia. Ann Med. 2004; 36 (7): 518-29.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac cachexia</article-title>
          <source>Ann Med</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>518</fpage>
          <lpage>29</lpage>
          <issue>7</issue>
          <volume>36</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Anker</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Steinborn</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Strassburg</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Sharma R, Coats    AJS, Anker SD. The role of inflammatory mediators in chronic heart failure:    cytokines, nitric oxide, and endothelin-1. Int J Cardiol. 2000; 72 (2): 175-86.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>175</fpage>
          <lpage>86</lpage>
          <issue>2</issue>
          <volume>72</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sharma</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Coats</surname>
              <given-names>AJS</given-names>
            </name>
            <name>
              <surname>Anker</surname>
              <given-names>SD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Kang Y-M, Ma    Y, Elks C, Zheng JP, Yang ZM, Francis J. Cross-talk between cytokines and renin-angiotensin    in hypothalamic paraventricular nucleus in heart failure: role of nuclear factor-{kappa}B.    Cardiovasc Res. 2008; 79 (4): 671-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cross-talk between cytokines and renin-angiotensin in hypothalamic paraventricular nucleus in heart failure: role of nuclear factor-{kappa}B</article-title>
          <source>Cardiovasc Res</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>671</fpage>
          <lpage>8</lpage>
          <issue>4</issue>
          <volume>79</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kang</surname>
              <given-names>Y-M</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Elks</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>ZM</given-names>
            </name>
            <name>
              <surname>Francis</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Zhang Z-H,    Wei S-G, Francis J, Felder RB. Cardiovascular and renal sympathetic activation    by blood-borne TNF-alpha in rat: the role of central prostaglandins. Am J Physiol    Regul Integr Comp Physiol. 2003; 284 (4): R916-27.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiovascular and renal sympathetic activation by blood-borne TNF-alpha in rat: the role of central prostaglandins</article-title>
          <source>Am J Physiol Regul Integr Comp Physiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>R916</fpage>
          <lpage>27</lpage>
          <issue>4</issue>
          <volume>284</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>Z-H</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>S-G</given-names>
            </name>
            <name>
              <surname>Francis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Felder</surname>
              <given-names>RB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Francis J,    Wei S-G, Weiss RM, Felder RB. Brain angiotensin-converting enzyme activity and    autonomic regulation in heart failure. Am J Physiol Heart Circ Physiol. 2004;    287 (5): H2138-46.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Brain angiotensin-converting enzyme activity and autonomic regulation in heart failure</article-title>
          <source>Am J Physiol Heart Circ Physiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>H2138</fpage>
          <lpage>46</lpage>
          <issue>5</issue>
          <volume>287</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Francis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>S-G</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Felder</surname>
              <given-names>RB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Adamopoulos    S, Parissis JT, Kremastinos DT. A glossary of circulating cytokines in chronic    heart failure. Eur J Heart Fail. 2001; 3 (5): 517-26.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A glossary of circulating cytokines in chronic heart failure</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>517</fpage>
          <lpage>26</lpage>
          <issue>5</issue>
          <volume>3</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Adamopoulos</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Parissis</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Kremastinos</surname>
              <given-names>DT</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Figueras M,    Busquets S, Carb&#243; N, Almendro V, Argiles JM, Lopez-Soriano FJ. Cancer    cachexia results in an increase in TNF-alpha receptor gene expression in both    skeletal muscle and adipose tissue. Int J Oncol. 2005; 27 (3): 855-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cancer cachexia results in an increase in TNF-alpha receptor gene expression in both skeletal muscle and adipose tissue</article-title>
          <source>Int J Oncol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>855</fpage>
          <lpage>60</lpage>
          <issue>3</issue>
          <volume>27</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Figueras</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Busquets</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Carb&#243;</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Almendro</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Argiles</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Lopez-Soriano</surname>
              <given-names>FJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Aderka D, Engelmann    H, Wysenbeek A, Levo Y. The possible role of tumor necrosis factor (TNF) and    its natural inhibitors, the soluble-TNF receptors, in autoimmune diseases. Isr    J Med Sci. 1992; 28 (2): 126-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The possible role of tumor necrosis factor (TNF) and its natural inhibitors, the soluble-TNF receptors, in autoimmune diseases</article-title>
          <source>Isr J Med Sci</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>126</fpage>
          <lpage>30</lpage>
          <issue>2</issue>
          <volume>28</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Aderka</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Engelmann</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wysenbeek</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Levo</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Valgimigli    M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, Francolini G, et al. Tumor    necrosis factor-{alpha} receptor 1 is a major predictor of mortality and new-onset    heart failure in patients with acute myocardial infarction: the cytokine-activation    and long-term prognosis in myocardial infarction (C-ALPHA) study. Circulation.    2005; 111 (7): 863-70.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Tumor necrosis factor-{alpha} receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the cytokine-activation and long-term prognosis in myocardial infarction (C-ALPHA) study</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>863</fpage>
          <lpage>70</lpage>
          <issue>7</issue>
          <volume>111</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Valgimigli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ceconi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Malagutti</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Merli</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Soukhomovskaia</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Francolini</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Levine B, Kalman    J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis    factor in severe chronic heart failure. N Engl J Med. 1990; 323 (4): 236-41.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Elevated circulating levels of tumor necrosis factor in severe chronic heart failure</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>236</fpage>
          <lpage>41</lpage>
          <issue>4</issue>
          <volume>323</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Levine</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kalman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mayer</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Fillit</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Packer</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Anker SD, Coats    AJS. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine    activation. Chest. 1999; 115 (3): 836-47.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation</article-title>
          <source>Chest</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>836</fpage>
          <lpage>47</lpage>
          <issue>3</issue>
          <volume>115</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Anker</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Coats</surname>
              <given-names>AJS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36. Behnke BJ,    Delp MD, McDonough P, Spier SA, Poole DC, Musch TI. Effects of chronic heart    failure on microvascular oxygen exchange dynamics in muscles of contrasting    fiber type. Cardiovasc Res. 2004; 61 (2): 325-32.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of chronic heart failure on microvascular oxygen exchange dynamics in muscles of contrasting fiber type</article-title>
          <source>Cardiovasc Res</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>325</fpage>
          <lpage>32</lpage>
          <issue>2</issue>
          <volume>61</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Behnke</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Delp</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>McDonough</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Spier</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Poole</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Musch</surname>
              <given-names>TI</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37. Paulus W, Kastner    S, Pujadas P, Shah AM, Drexler H, Vanderheyden M. Left ventricular contractile    effects of inducible nitric oxide synthase in the human allograft. Circulation.    1997; 96: 3436-42.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular contractile effects of inducible nitric oxide synthase in the human allograft</article-title>
          <source>Circulation</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>3436</fpage>
          <lpage>42</lpage>
          <volume>96</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Paulus</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Kastner</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pujadas</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Drexler</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Vanderheyden</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38. Ferrari R.    Tumor necrosis factor in CHF: a double facet cytokine. Cardiovasc Res. 1998;    37 (3): 554-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Tumor necrosis factor in CHF: a double facet cytokine</article-title>
          <source>Cardiovasc Res</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>554</fpage>
          <lpage>9</lpage>
          <issue>3</issue>
          <volume>37</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ferrari</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B39">
        <mixed-citation>39. Anker SD, Rauchhaus    M. Heart failure as a metabolic problem. Eur J Heart Fail. 1999; 1 (2): 127-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Heart failure as a metabolic problem</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>127</fpage>
          <lpage>31</lpage>
          <issue>2</issue>
          <volume>1</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Anker</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Rauchhaus</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B40">
        <mixed-citation>40. Duscha BD,    Annex BH, Green HJ, Pippen AM, Kraus WE. Deconditioning fails to explain peripheral    skeletal muscle alterations in men with chronic heart failure. J Am Coll Cardiol.    2002; 39 (7): 1170-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Deconditioning fails to explain peripheral skeletal muscle alterations in men with chronic heart failure</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1170</fpage>
          <lpage>4</lpage>
          <issue>7</issue>
          <volume>39</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Duscha</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Annex</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Pippen</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Kraus</surname>
              <given-names>WE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B41">
        <mixed-citation>41. Batista ML    Jr, Santos R, Cunha LM, Mattos K, Oliveira EM, Seelaender MC, et al. Changes    in the pro-inflammatory cytokine production and peritoneal macrophage function    in rats with chronic heart failure. Cytokine. 2006; 34 (5-6): 284-90.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Changes in the pro-inflammatory cytokine production and peritoneal macrophage function in rats with chronic heart failure</article-title>
          <source>Cytokine</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>284</fpage>
          <lpage>90</lpage>
          <issue>5-6</issue>
          <volume>34</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Batista</surname>
              <given-names>ML Jr</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cunha</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Mattos</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Seelaender</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B42">
        <mixed-citation>42. Sasayama S,    Matsumori A, Kihara Y. New insights into the pathophysiological role for cytokines    in heart failure. Cardiovasc Res. 1999; 42 (3): 557-64.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>New insights into the pathophysiological role for cytokines in heart failure</article-title>
          <source>Cardiovasc Res</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>557</fpage>
          <lpage>64</lpage>
          <issue>3</issue>
          <volume>42</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sasayama</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Matsumori</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kihara</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B43">
        <mixed-citation>43. Gullestad L,    Semb AG, Holt E, Sk&#228;rdal R, Ueland T, Yndestad A. Effect of thalidomide    in patients with chronic heart failure. Am Heart J. 2002; 144 (5): 847-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of thalidomide in patients with chronic heart failure</article-title>
          <source>Am Heart J</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>847</fpage>
          <lpage>50</lpage>
          <issue>5</issue>
          <volume>144</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gullestad</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Semb</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Holt</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sk&#228;rdal</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ueland</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yndestad</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B44">
        <mixed-citation>44. Nozaki N, Yamaguchi    S, Yamaoka M, Okuyama M, Nakamura H. Enhanced expression and shedding of tumor    necrosis factor (TNF) receptors from mononuclear leukocytes in human heart failure.    J Moll Cell Cardiol. 1998; 30: 2003-12.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Enhanced expression and shedding of tumor necrosis factor (TNF) receptors from mononuclear leukocytes in human heart failure</article-title>
          <source>J Moll Cell Cardiol</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>2003</fpage>
          <lpage>12</lpage>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nozaki</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yamaguchi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yamaoka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Okuyama</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B45">
        <mixed-citation>45. Bolger AP,    Sharma R, von Haehling S, Doehner W, Oliver B, Rauchaus M, et al. Effect of    interleukin-10 on the production of tumor necrosis factor-alpha by peripheral    blood mononuclear cells from patients with chronic heart failure. Am J Cardiol.    2002; 90 (4): 384-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>384</fpage>
          <lpage>9</lpage>
          <issue>4</issue>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bolger</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>von Haehling</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Doehner</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Oliver</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Rauchaus</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B46">
        <mixed-citation>46. Mallat Z, Besnard    S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, et al. Protective role of interleukin-10    in atherosclerosis. Circ Res. 1999; 85 (8): e17-24.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Protective role of interleukin-10 in atherosclerosis</article-title>
          <source>Circ Res</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>e17</fpage>
          <lpage>24</lpage>
          <issue>8</issue>
          <volume>85</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mallat</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Besnard</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Duriez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Deleuze</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Emmanuel</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bureau</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B47">
        <mixed-citation>47. Denys A, Udalova    IA, Smith C, Williams LM, Ciesielski CJ, Campbell J, et al. Evidence for a dual    mechanism for IL-10 suppression of TNF-{alpha} production that does not involve    inhibition of p38 mitogen-activated protein kinase or NF-{kappa}B in primary    human macrophages. J Immunol. 2002; 168 (10): 4837-45.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Evidence for a dual mechanism for IL-10 suppression of TNF-{alpha} production that does not involve inhibition of p38 mitogen-activated protein kinase or NF-{kappa}B in primary human macrophages</article-title>
          <source>J Immunol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>4837</fpage>
          <lpage>45</lpage>
          <issue>10</issue>
          <volume>168</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Denys</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Udalova</surname>
              <given-names>IA</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Ciesielski</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Campbell</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B48">
        <mixed-citation>48. Kaur K, Sharma    AK, Dhingra S, Singra PK. Interplay of TNF-alpha and IL-10 in regulating oxidative    stress in isolated adult cardiac myocytes. J Mol Cell Cardiol. 2006; 41 (6):    1023-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Interplay of TNF-alpha and IL-10 in regulating oxidative stress in isolated adult cardiac myocytes</article-title>
          <source>J Mol Cell Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1023</fpage>
          <lpage>30</lpage>
          <issue>6</issue>
          <volume>41</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kaur</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Dhingra</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Singra</surname>
              <given-names>PK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B49">
        <mixed-citation>49. Yu Y, Zhang    Z-H, Wei S-G, Chu Y, Weiss RM, Heistad DD, et al. Central gene transfer of interleukin-10    reduces hypothalamic inflammation and evidence of heart failure in rats after    myocardial infarction. Circ Res. 2007; 101 (3): 304-12.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Central gene transfer of interleukin-10 reduces hypothalamic inflammation and evidence of heart failure in rats after myocardial infarction</article-title>
          <source>Circ Res</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>304</fpage>
          <lpage>12</lpage>
          <issue>3</issue>
          <volume>101</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Z-H</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>S-G</given-names>
            </name>
            <name>
              <surname>Chu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Heistad</surname>
              <given-names>DD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B50">
        <mixed-citation>50. Silva MSV,    Bocchi EA, Guimar&#227;es GV, Padovani CR, Silva MN, Pereira SF. et al. Benefits    of exercise training in the treatment of heart failure: study with a control    group. Arq Bras Cardiol. 2002; 79: 351-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>et al: Benefits of exercise training in the treatment of heart failure: study with a control group</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>351</fpage>
          <lpage>62</lpage>
          <volume>79</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Silva</surname>
              <given-names>MSV</given-names>
            </name>
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Guimar&#227;es</surname>
              <given-names>GV</given-names>
            </name>
            <name>
              <surname>Padovani</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>SF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B51">
        <mixed-citation>51. Wisloff U,    Stoylen A, Loennechen JP, Bruvold M, Rognmo O, Haram PM, et al. Superior cardiovascular    effect of aerobic interval training versus moderate continuous training in heart    failure patients: a randomized study. Circulation. 2007; 115 (24): 3086-94.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study</article-title>
          <source>Circulation</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>3086</fpage>
          <lpage>94</lpage>
          <issue>24</issue>
          <volume>115</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wisloff</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Stoylen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Loennechen</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Bruvold</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rognmo</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Haram</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B52">
        <mixed-citation>52. Carvalho RT,    Vieira MLC, Romano A, Kopel L, Lage SG. Exerc&#237;cio resistido na avalia&#231;&#227;o    da disfun&#231;&#227;o endotelial na insufici&#234;ncia card&#237;aca.    Arq Bras Cardiol. 2006; 86: 459-65.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exerc&#237;cio resistido na avalia&#231;&#227;o da disfun&#231;&#227;o endotelial na insufici&#234;ncia card&#237;aca</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>459</fpage>
          <lpage>65</lpage>
          <volume>86</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Carvalho</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Vieira</surname>
              <given-names>MLC</given-names>
            </name>
            <name>
              <surname>Romano</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kopel</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lage</surname>
              <given-names>SG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B53">
        <mixed-citation>53. Niebauer J.    Effects of exercise training on inflammatory markers in patients with heart    failure. Heart Fail Rev. 2008; 13 (1): 39-49.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of exercise training on inflammatory markers in patients with heart failure</article-title>
          <source>Heart Fail Rev</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>39</fpage>
          <lpage>49</lpage>
          <issue>1</issue>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Niebauer</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B54">
        <mixed-citation>54. Adamopoulos    S, Parissis J, Kroupis C, Georgiadis M, Karatzas D, Karavolias G, et al. Physical    training reduces peripheral markers of inflammation in patients with chronic    heart failure. Eur Heart J. 2001; 22 (9): 791-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Physical training reduces peripheral markers of inflammation in patients with chronic heart failure</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>791</fpage>
          <lpage>7</lpage>
          <issue>9</issue>
          <volume>22</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Adamopoulos</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Parissis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kroupis</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Georgiadis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Karatzas</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Karavolias</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B55">
        <mixed-citation>55. Adamopoulos    S, Parissis J, Karatzas D, Kroupis L, Georgiadis M, Karavolias G, et al. Physical    training modulates proinflammatory cytokines and the soluble Fas/soluble Fas/ligand    system in patients with chronic heart failure. J Am Coll Cardiol. 2002; 39 (4):    653-63.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas/ligand system in patients with chronic heart failure</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>653</fpage>
          <lpage>63</lpage>
          <issue>4</issue>
          <volume>39</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Adamopoulos</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Parissis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Karatzas</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kroupis</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Georgiadis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Karavolias</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B56">
        <mixed-citation>56. Conraads VM,    Beckers P, Bosmans J, De Clerck LS, Stevens WJ, Vrints CJ, et al. Combined endurance/resistance    training reduces plasma TNF-{alpha} receptor levels in patients with chronic    heart failure and coronary artery disease. Eur Heart J. 2002; 23 (23): 1854-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Combined endurance/resistance training reduces plasma TNF-{alpha} receptor levels in patients with chronic heart failure and coronary artery disease</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1854</fpage>
          <lpage>60</lpage>
          <issue>23</issue>
          <volume>23</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Conraads</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Beckers</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bosmans</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>De Clerck</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Stevens</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Vrints</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B57">
        <mixed-citation>57. Costa Rosa    LFBP, Batista Jr M. Efeito do treinamento f&#237;sico como modulador positivo    nas altera&#231;&#245;es no eixo neuroimunoend&#243;crino em indiv&#237;duos    com insufici&#234;ncia card&#237;aca cr&#244;nica: Poss&#237;vel atua&#231;&#227;o    do fator de necrose tumoral-&#945;.    Rev Bras Med Esporte. 2005; 11 (4): 238-42.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Efeito do treinamento f&#237;sico como modulador positivo nas altera&#231;&#245;es no eixo neuroimunoend&#243;crino em indiv&#237;duos com insufici&#234;ncia card&#237;aca cr&#244;nica: Poss&#237;vel atua&#231;&#227;o do fator de necrose tumoral-&#945;</article-title>
          <source>Rev Bras Med Esporte</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>238</fpage>
          <lpage>42</lpage>
          <issue>4</issue>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Costa Rosa</surname>
              <given-names>LFBP</given-names>
            </name>
            <name>
              <surname>Batista Jr</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B58">
        <mixed-citation>58. Gielen S, Adams    V, Mobius-Winkler S, Linke S, Erbs J, Yu W, et al. Anti-inflammatory effects    of exercise training in the skeletal muscle of patients with chronic heart failure.    J Am Coll Cardiol. 2003; 42 (5): 861-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>861</fpage>
          <lpage>8</lpage>
          <issue>5</issue>
          <volume>42</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gielen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Mobius-Winkler</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Linke</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Erbs</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B59">
        <mixed-citation>59. Pedersen BK,    Fischer CP. Beneficial health effects of exercise - the role of IL-6 as a myokine.    Trends Pharmacol Sci. 2007; 28 (4): 152-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Beneficial health effects of exercise - the role of IL-6 as a myokine</article-title>
          <source>Trends Pharmacol Sci</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>152</fpage>
          <lpage>6</lpage>
          <issue>4</issue>
          <volume>28</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pedersen</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>CP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B60">
        <mixed-citation>60. Petersen AMW,    Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol. 2005;    98 (4): 1154-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The anti-inflammatory effect of exercise</article-title>
          <source>J Appl Physiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1154</fpage>
          <lpage>62</lpage>
          <issue>4</issue>
          <volume>98</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Petersen</surname>
              <given-names>AMW</given-names>
            </name>
            <name>
              <surname>Pedersen</surname>
              <given-names>BK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B61">
        <mixed-citation>61. Fischer C,    Berntsen A, Perstrup L, Perstrup LB, Eskildsen P, Pedersen BK. Plasma levels    of interleukin-6 and C-reactive protein are associated with physical inactivity    independent of obesity. Scand J Med Sci Sports. 2007; 17 (5): 580-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Plasma levels of interleukin-6 and C-reactive protein are associated with physical inactivity independent of obesity</article-title>
          <source>Scand J Med Sci Sports</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>580</fpage>
          <lpage>7</lpage>
          <issue>5</issue>
          <volume>17</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fischer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Berntsen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Perstrup</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Perstrup</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Eskildsen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pedersen</surname>
              <given-names>BK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B62">
        <mixed-citation>62. Flynn MG, McFarlin    BK, Markofski MM. State of the art reviews: The anti-inflammatory actions of    exercise training. Am J Lifestyle Med. 2007; 1 (3): 220-35.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>State of the art reviews: The anti-inflammatory actions of exercise training</article-title>
          <source>Am J Lifestyle Med</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>220</fpage>
          <lpage>35</lpage>
          <issue>3</issue>
          <volume>1</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Flynn</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>McFarlin</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Markofski</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B63">
        <mixed-citation>63. Fischer C.    Interleukin-6 in acute exercise and training: what is the biological relevance?    Exerc Immunol Rev. 2006; 12: 6-33.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Interleukin-6 in acute exercise and training: what is the biological relevance?</article-title>
          <source>Exerc Immunol Rev</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>6</fpage>
          <lpage>33</lpage>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fischer</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B64">
        <mixed-citation>64. Starkie R,    Ostrowski SR, Jauffred S, Febbraio MA, Pedersen BK. Exercise and IL-6 infusion    inhibit endotoxin-induced TNF-{alpha} production in humans. FASEB J. 2003; 17    (8): 884-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise and IL-6 infusion inhibit endotoxin-induced TNF-{alpha} production in humans</article-title>
          <source>FASEB J</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>884</fpage>
          <lpage>6</lpage>
          <issue>8</issue>
          <volume>17</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Starkie</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ostrowski</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Jauffred</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Febbraio</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Pedersen</surname>
              <given-names>BK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B65">
        <mixed-citation>65. Keller C, Keller    P, Giralt M, Hidalgo BK. Exercise normalises overexpression of TNF-alpha in    knockout mice. Biochem Biophys Res Commun. 2004; 321 (1): 179-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise normalises overexpression of TNF-alpha in knockout mice</article-title>
          <source>Biochem Biophys Res Commun</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>179</fpage>
          <lpage>82</lpage>
          <issue>1</issue>
          <volume>321</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Keller</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Keller</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Giralt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hidalgo</surname>
              <given-names>BK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B66">
        <mixed-citation>66. Gullestad L,    Kjekshus J, Damas JK, Ueland T, Yndestad A, Aukrust P. Agents targeting inflammation    in heart failure. Expert Opinion on Investigational Drugs. 2005; 14 (5): 557-66.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Agents targeting inflammation in heart failure</article-title>
          <source>Expert Opinion on Investigational Drugs</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>557</fpage>
          <lpage>66</lpage>
          <issue>5</issue>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gullestad</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kjekshus</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Damas</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Ueland</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yndestad</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Aukrust</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B67">
        <mixed-citation>67. Kjekshus J,    Apetrei E, Barrios V, Bohm M, Cleland JGF, Cornel JH, et al. Rosuvastatin in    older patients with systolic heart failure. N Engl J Med. 2007; 357 (22): 2248-61.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Rosuvastatin in older patients with systolic heart failure</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2248</fpage>
          <lpage>61</lpage>
          <issue>22</issue>
          <volume>357</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kjekshus</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Apetrei</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Barrios</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Bohm</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cleland</surname>
              <given-names>JGF</given-names>
            </name>
            <name>
              <surname>Cornel</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B68">
        <mixed-citation>68. Spangenburg    EE, Brown DA, Johnson MS, Moore RL. Exercise increases SOCS-3 expression in    rat skeletal muscle: potential relationship to IL-6 expression. J Physiol. 2006;    572 (3): 839-48.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise increases SOCS-3 expression in rat skeletal muscle: potential relationship to IL-6 expression</article-title>
          <source>J Physiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>839</fpage>
          <lpage>48</lpage>
          <issue>3</issue>
          <volume>572</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Spangenburg</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>RL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B69">
        <mixed-citation>69. Sriwijitkamol    A, Christ-Roberts C, Berria R, Eagan P, Pratipanawatr T, DeFronzo RA,et al.    Reduced skeletal muscle inhibitor of {kappa}B{beta} content is associated with    insulin resistance in subjects with type 2 diabetes: reversal by exercise training.    Diabetes. 2006; 55 (3): 760-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Reduced skeletal muscle inhibitor of {kappa}B{beta} content is associated with insulin resistance in subjects with type 2 diabetes: reversal by exercise training</article-title>
          <source>Diabetes</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>760</fpage>
          <lpage>7</lpage>
          <issue>3</issue>
          <volume>55</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sriwijitkamol</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Christ-Roberts</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Berria</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Eagan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pratipanawatr</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>DeFronzo</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Efecto antiinflamatorio del entrenamiento f&#237;sico en la insuficiencia cardiaca: rol del TNF-&#945; y de la IL-10</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>En los &#250;ltimos 50 a&#241;os, la comprensi&#243;n sobre las alteraciones deteriorativas involucradas en la progresi&#243;n de la insuficiencia cardiaca (IC), descriptas inicialmente como causadas por alteraciones en la retenci&#243;n de sales y fluidos, o alteraciones en los par&#225;metros hemodin&#225;micos, ha cambiado significativamente. Recientemente, diversos estudios en pacientes con IC han demostrado niveles plasm&#225;ticos (o en el suero) alterados de citosinas proinflamatorias, tales como el factor &#945; de necrosis tumoral (TNF-&#945;), las interleuquinas 1, 6 y 18, y la cardiotropina-1, entre otros marcadores inflamatorios. Esas alteraciones se mostraron independientes de la etiolog&#237;a de la IC, sugiriendo una v&#237;a patog&#233;nica com&#250;n. En respuesta a esos nuevos hallazgos, se vienen proponiendo intervenciones en el sentido de evitar y/o reducir esas alteraciones inflamatorias. Se viene relatando previamente los beneficios cardiovasculares, inducidos por el entrenamiento aerobio realizado en intensidad variando de ligera a moderada. Adem&#225;s, se est&#225; demostrando que el entrenamiento f&#237;sico (aerobio moderado) parece capaz de modular, en la vigencia de un cuadro inflamatorio cr&#243;nico anormal, la expresi&#243;n elevada de citosinas proinflamatorias, mol&#233;culas de adhesi&#243;n solubles, factores quimioatractantes y estr&#233;s oxidactivo. Tomados en conjunto, esos datos indican un posible efecto Antiinflamatorio inducido por el entrenamiento f&#237;sico. As&#237;, esta revisi&#243;n tiene por objeto abordar el entrenamiento f&#237;sico como una alternativa no farmacol&#243;gica adyuvante que se administrar&#225; en algunos cuadros patol&#243;gicos donde predominan las alteraciones cr&#243;nicas del TNF-&#945;, como en la IC. A su vez, el "efecto antiinflamatorio" que el entrenamiento f&#237;sico induce parece mediarse sobre todo por la IL-10.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Ejercicio</kwd>
        <kwd>insuficiencia cardiaca</kwd>
        <kwd>enfermedad de la arteria coronaria</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO DE REVISI&#211;N</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Efecto antiinflamatorio del entrenamiento f&#237;sico en la insuficiencia cardiaca: rol del TNF-</bold>
          </label>
          <p>
            <bold>&#945; y de la IL-10</bold>
          </p>
        </fn>
      </p>
      <p>
        <bold>Miguel Luiz Batista J&#250;nior<sup>I</sup>; Renato Delascio Lopes<sup>II, III</sup>; Mar&#237;lia Cerqueira Leite Seelaender<sup>I</sup>; Antonio Carlos Lopes<sup>II</sup></bold>
      </p>
      <p><sup>I</sup>Grupo de Biolog&#237;a Molecular de la C&#233;lula - Instituto de Ciencias Biom&#233;dicas I y Departamento de Medicina Interna - Universidad Federal de San Pablo, SP, Brasil</p>
      <p><sup>II</sup>Departamento de Medicina Interna, Universidad Federal de San Pablo, SP, Brasil</p>
      <p><sup>III</sup>Duke Clinical Research Institute, Durham- North Caroline, USA</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p>En los &#250;ltimos 50 a&#241;os, la comprensi&#243;n sobre las alteraciones deteriorativas involucradas en la progresi&#243;n de la insuficiencia cardiaca (IC), descriptas inicialmente como causadas por alteraciones en la retenci&#243;n de sales y fluidos, o alteraciones en los par&#225;metros hemodin&#225;micos, ha cambiado significativamente. Recientemente, diversos estudios en pacientes con IC han demostrado niveles plasm&#225;ticos (o en el suero) alterados de citosinas proinflamatorias, tales como el factor &#945; de necrosis tumoral (TNF-&#945;), las interleuquinas 1, 6 y 18, y la cardiotropina-1, entre otros marcadores inflamatorios. Esas alteraciones se mostraron independientes de la etiolog&#237;a de la IC, sugiriendo una v&#237;a patog&#233;nica com&#250;n. En respuesta a esos nuevos hallazgos, se vienen proponiendo intervenciones en el sentido de evitar y/o reducir esas alteraciones inflamatorias.</p>
      <p> Se viene relatando previamente los beneficios cardiovasculares, inducidos por el entrenamiento aerobio realizado en intensidad variando de ligera a moderada. Adem&#225;s, se est&#225; demostrando que el entrenamiento f&#237;sico (aerobio moderado) parece capaz de modular, en la vigencia de un cuadro inflamatorio cr&#243;nico anormal, la expresi&#243;n elevada de citosinas proinflamatorias, mol&#233;culas de adhesi&#243;n solubles, factores quimioatractantes y estr&#233;s oxidactivo. Tomados en conjunto, esos datos indican un posible efecto Antiinflamatorio inducido por el entrenamiento f&#237;sico.</p>
      <p> As&#237;, esta revisi&#243;n tiene por objeto abordar el entrenamiento f&#237;sico como una alternativa no farmacol&#243;gica adyuvante que se administrar&#225; en algunos cuadros patol&#243;gicos donde predominan las alteraciones cr&#243;nicas del TNF-&#945;, como en la IC. A su vez, el "efecto antiinflamatorio" que el entrenamiento f&#237;sico induce parece mediarse sobre todo por la IL-10.</p>
      <p><bold>Palabras claves: </bold> Ejercicio, insuficiencia cardiaca, enfermedad de la arteria coronaria, interleuquinas.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La insuficiencia cardiaca (IC) es un s&#237;ndrome cl&#237;nico de fisiopatolog&#237;a compleja, que puede resultar de cualquier disfunci&#243;n funcional o estructural que afecte el coraz&#243;n, y en consecuencia, comprometa la capacidad de los ventr&#237;culos de llenar y bombear sangre de manera satisfactoria<sup>1,2</sup>. Las manifestaciones cardinales de la IC son disnea y fatiga, que pueden limitar la capacidad de realizar el esfuerzo f&#237;sico (intolerancia al ejercicio f&#237;sico) y pueden culminar en procesos que conducen a la congesti&#243;n pulmonar sist&#233;mica y al aumento de la resistencia vascular perif&#233;rica<sup>1,3,4</sup>. Las principales causas de origen cardiaco de la IC son las enfermedades de las arterias coronarias, la hipertensi&#243;n, las cardiomiopat&#237;as dilatadas y las enfermedades de las v&#225;lvulas cardiacas<sup>1,2</sup>.</p>
      <p>Actualmente, las alteraciones deteriorativas involucradas en la progresi&#243;n de la IC, que se comprendi&#243; anteriormente como causadas por alteraciones en la retenci&#243;n de sal y de agua o de alteraciones en los par&#225;metros hemodin&#225;micos, han sido descriptas como recurrentes de procesos que culminan en la activaci&#243;n inflamatoria local y sist&#233;mica<sup>5-9</sup>, evidenciadas por el aumento en la expresi&#243;n g&#233;nica y en la producci&#243;n de citosinas proinflamatorias como: Factor &#945; de necrosis tumoral (TNF-&#945;); interleuquinas 1&#946; (IL-1&#946;), 6 (IL-6) y 18 (IL-18); cardiotropina-1; quimosinas CC y CXC; entre otros marcadores inflamatorios, en el plasma, m&#250;sculo-esquel&#233;ticos y cardiacos, as&#237; como en linfocitos perif&#233;ricos en ratones y pacientes con IC. Esos mediadores inflamatorios pueden, adem&#225;s de contribuir para la fisiopatolog&#237;a y progresi&#243;n estructural y funcional del m&#250;sculo cardiaco, actuar directamente en el aparecimiento de las manifestaciones perif&#233;ricas del s&#237;ndrome de la IC, sobre todo en las alteraciones relacionadas a la disminuci&#243;n de la masa muscular y de las alteraciones funcionales<sup>10,11</sup>, entre otras.</p>
      <p>Siguiendo esa l&#237;nea de razonamiento, Coats et al.<sup>7</sup> propusieron una hip&#243;tesis intitulada "Hip&#243;tesis muscular de la IC", seg&#250;n la que, las alteraciones degenerativas se originan de una perfusi&#243;n reducida en los m&#250;sculos esquel&#233;ticos ocasiona por el bajo gasto cardiaco, resultando en una hipoxia tisular. Si se mantienen por un largo tiempo, la hipoxia tisular y un consecuente aumento en la producci&#243;n de radicales libres pasan a ser un potente est&#237;mulo para la producci&#243;n de citosinas proinflamatorias (TNF-&#945;, IL-1&#946; y IL-6), mediada por el factor de transcripci&#243;n nuclear &#954;B (NF-&#954;B), que iniciar&#237;a una cascada de eventos que consiste en la expresi&#243;n de la &#243;xido n&#237;trico sintetasa inducible (iNOS), la apoptosis del m&#250;sculo esquel&#233;tico y la p&#233;rdida de masa muscular<sup>5,11-13</sup>.</p>
      <p>Por consiguiente, pese a que en los &#250;ltimos a&#241;os la gran mayor&#237;a de los estudios sobre IC haya enfocado las citosinas proinflamatorias, actualmente, las citosinas antiinflamatorias -en especial la IL-10- se han destacado y pueden tener un rol importante en la fisiopatolog&#237;a de la IC<sup>14,15</sup>. En pacientes con IC, se viene relatando una disminuci&#243;n en la concentraci&#243;n plasm&#225;tica de IL-10 se ha relatado y correlacionado positivamente con un empeoramiento en la fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo<sup>16</sup>. Adem&#225;s, en animales con IC inducida por el IM, recientemente la utilizaci&#243;n de la relaci&#243;n de la producci&#243;n de la IL-10 por el TNF-&#945; (tasa IL-10/ TNF-&#945;) se ha mostrado como un indicador con mayor precisi&#243;n del grado de disfunci&#243;n ventricular en esa condici&#243;n<sup>14,17</sup>.</p>
      <p>El entrenamiento f&#237;sico, realizado sobre todo a trav&#233;s de ejercicios aerobios, se est&#225; considerando como la base de sustentaci&#243;n de los programas de rehabilitaci&#243;n cardiaca y una importante forma de tratamiento no farmacol&#243;gico, a trav&#233;s del que se pueden alcanzar los objetivos establecidos para minimizar los factores de riesgo que predisponen al individuo a las enfermedades cardiovasculares<sup>18,19</sup>.</p>
      <p>Adem&#225;s de los beneficios cardiovasculares, inducidos tanto por las adaptaciones en la funci&#243;n del coraz&#243;n como una bomba, como en las adaptaciones perif&#233;ricas, el entrenamiento f&#237;sico parece capaz de modular, en la vigencia de un cuadro inflamatorio cr&#243;nico anormal, la expresi&#243;n de citosinas proinflamatorias, mol&#233;culas de adhesi&#243;n solubles y factores quimioatractantes<sup>8,20</sup>. La utilizaci&#243;n del entrenamiento aerobio en una estera ergom&#233;trica al 70% VO<sub>2pico</sub>, durante seis meses, fue capaz de atenuar la expresi&#243;n local aumentada de citosinas proinflamatorias (TNF-&#945;, IL-1&#946;, IL-6) en el m&#250;sculo estriado esquel&#233;tico en pacientes con IC. A&#250;n en el mismo estudio, se demostr&#243; que se asoci&#243; esta reducci&#243;n a la reducci&#243;n en la expresi&#243;n del gen de la isoforma inducible de la &#243;xido n&#237;trico sintetasa (&#237;ONS) y al acumulaci&#243;n intracelular de &#243;xido n&#237;trico (EN EL), sugiriendo entonces que la utilizaci&#243;n del entrenamiento f&#237;sico deba realizarse no solo como una forma de intervenci&#243;n que objetiva la mejora de las capacidades f&#237;sicas (comprometidas o no por el IC), sino como una estrategia terap&#233;utica con la finalidad antiinflamatoria local.</p>
      <p>En ese aspecto, estudios vienen revelando alteraciones en la concentraci&#243;n plasm&#225;tica de IL-10 y IL-ra (receptor antagonista para IL-1) tras el ejercicio f&#237;sico, condici&#243;n que puede contribuir al <italic>milieu</italic> antiinflamatorio, y as&#237;, ser un importante mediador de los efectos antiinflamatorios del entrenamiento f&#237;sico. La IL-10 puede actuar en diferentes tipos celulares e induce la supresi&#243;n de la respuesta inflamatoria en los m&#225;s variados tipos celulares<sup>21</sup>. Adem&#225;s, se est&#225; postulando dicha citosina como la principal mol&#233;cula responsable del "orquestamiento" de reacciones inflamatorias, en particular la inhibici&#243;n de las alteraciones mediadas por el TNF-&#945;<sup>21,22</sup>.</p>
      <p>Por otra parte, pese al aumento creciente de evidencias indicando la relaci&#243;n entre el efecto antiinflamatorio del ejercicio f&#237;sico, as&#237; como su efecto protector y/o inhibidor en varios cuadros patol&#243;gicos, los posibles efectos a lo largo del tiempo (entrenamiento) no est&#225;n todav&#237;a bien caracterizados.</p>
      <p>Por lo tanto, se puede concluir que, solo recientemente se ha enfocado el posible efecto antiinflamatorio del entrenamiento f&#237;sico sobre la producci&#243;n de citosinas pro (TNF-&#945;) y antiinflamatoria (IL-10) en pacientes con IC. Por otra parte, las adaptaciones oriundas del entrenamiento aerobio moderado ( al 55% - 65% VO<sub>2pico</sub>) pueden tener efectos inmunomoduladores, especialmente en la producci&#243;n de la IL-10, condici&#243;n que podr&#237;a ser todav&#237;a m&#225;s evidente en cuadros patol&#243;gicos que presentan, de manera cr&#243;nica, un aumento en la producci&#243;n de esos marcadores inflamatorios. Adem&#225;s, el aumento de la actividad f&#237;sica es cr&#237;tico en el tratamiento adyuvante de pacientes con IC, dependiendo, naturalmente, de la intensidad de esa reducci&#243;n en la gravedad de la enfermedad.</p>
      <p><bold>Rol del TNF-</bold>&#945; <bold>en la progresi&#243;n de la IC</bold></p>
      <p>Como lo descrito arriba, las citosinas proinflamatorias, en especial el TNF-&#945;, as&#237; como otros mediadores inflamatorios, como las quimosinas, tienen un rol de destaque en varios niveles de la IC, siendo que, en el inicio, a pesar de que su liberaci&#243;n tenga una funci&#243;n restauradora o reparadora, cuando mantenidas a lo largo del tiempo, pueden tener un papel importante en la modulaci&#243;n de las alteraciones deteriorativas del cuadro de IC<sup>23</sup>. Esos datos se corroboran de otros provenientes de estudios en modelos en que se indujo experimentalmente niveles elevados de mediadores inflamatorios con el TNF-&#945; y el &#243;xido n&#237;trico, a fin de mimetizar algunas alteraciones cl&#237;nicas caracter&#237;sticas de la IC, tales como disfunci&#243;n progresiva del ventr&#237;culo izquierdo, edema pulmonar y cardiomiopatias<sup>24</sup>. A&#250;n, alteraciones detectadas en los niveles plasm&#225;ticos presentan correlaci&#243;n con varios marcadores de disfunciones caracter&#237;sticas de la IC, adem&#225;s de ser marcadoras de pron&#243;stico y severidad de la misma<sup>25,26</sup>.</p>
      <p>Adem&#225;s de las alteraciones en los niveles plasm&#225;ticos, un estudio reciente<sup>27</sup> demostr&#243; correlaciones positivas entre los niveles de TNF-&#945; en el miocito cardiaco y en el n&#250;cleo paraventricular en el hipot&#225;lamo en ratones con IC. Por a&#241;adidura, esas alteraciones se relacionaron a la mayor excitaci&#243;n neurohumoral en la regi&#243;n cardiovascular cerebral<sup>28</sup>, y, juntamente con una mayor activaci&#243;n del sistema renina-angiotensina<sup>29</sup>, sugieren una posible interacci&#243;n entre esos sistemas (inmune x renina-angiotensina) y modular alteraciones como retenci&#243;n de sodio y agua y en los procesos de remodelaci&#243;n cardiaca en ratones con IC.</p>
      <p>Se describi&#243; el TNF-&#945; en 1975 que se nombr&#243; inicialmente como caquexina, debido a su potente efecto citot&#243;xico contra c&#233;lulas tumorales<sup>23,25</sup>. Es un polipept&#237;dico trim&#233;rico (17 kDa), producido sobre todo por monocitos y macr&#243;fagos activados, adem&#225;s de otras c&#233;lulas, como: linfocitos, fibroblastos, neutr&#243;filos, m&#250;sculo liso y mastocitos<sup>23,30</sup>. Esa citosina puede actuar en casi todos los tipos de c&#233;lulas nucleadas, a trav&#233;s de dos tipos de receptores de membrana, tipo I (RTNF-I, p55) y tipo II (RTNF-II, p75), o como mol&#233;cula soluble, ambos activos biol&#243;gicamente<sup>8,23</sup>.</p>
      <p>Estudios anteriores demostraron la presencia de ambos tipos de receptores, tanto en el m&#250;sculo esquel&#233;tico<sup>31</sup> como en el cardiaco<sup>8</sup>. Tras la translaci&#243;n, similarmente al propio TNF-&#945;, se insertan ambos receptores en la membrana celular. En el clivaje proteol&#237;tico, realizado por una metaloproteinasa conversora de TNF-&#945; (TACE), se liberan los RTNF, bien como el propio TNF-&#945;, en su forma soluble. As&#237;, los fragmentos de los dominios extracelulares de ambos los receptores de TNF-&#945; (tipo I y II) pueden liberarse de la membrana celular y cuantificarse en su forma soluble (RsTNF-I y RsTNF-II), en la orina y en el plasma, se&#241;alados como reguladores de la actividad biol&#243;gica de esta citosina<sup>32</sup>.</p>
      <p>En concentraciones fisiol&#243;gicas, los RsTNF pueden actuar como un "reservatorio de liberaci&#243;n lenta", aumentando de esa forma el promedio de vida de esta citosina<sup>23,33</sup>. Cuando presente en concentraciones elevadas, como en pacientes con IC severa (clase III y IV, NYHA), los RsTNF pueden inhibir el aumento patol&#243;gico de la actividad del TNF-&#945;, actuando de esa forma como una antimol&#233;cula de TNF-&#945;<sup>8</sup>.</p>
      <p>En el 1990, Lavine et al.<sup>34</sup> observaron que pacientes con IC presentaron niveles medios aumentados de esa citosina (115 &#177; 25 x 9 &#177; 3 U/mL), cuando comparados a individuos sin la enfermedad. Tambi&#233;n demostraron que cuanto mayor el aumento, mayor la tendencia de esos pacientes para desarrollar un cuadro de caquexia cardiaca. Estudios recientes han demostrado concentraciones elevadas de TNF-&#945; en individuos portadores de caquexia cardiaca, siendo esa citosina un importante predictor de p&#233;rdida de peso<sup>35</sup>.</p>
      <p>El TNF-&#945; puede ser el principal causador de una serie de disturbios metab&#243;licos presentes en individuos con IC, tales como: elevada tasa metab&#243;lica<sup>25</sup>; disminuci&#243;n del flujo de sangre para tejidos perif&#233;ricos y disfunci&#243;n endotelial<sup>7,36</sup>; activaci&#243;n de la &#237;ONS<sup>11,37</sup>; y alteraci&#243;n en el metabolismo de las prote&#237;nas y de los lip&#237;deos<sup>38</sup>. Adem&#225;s de su conocido efecto termog&#233;nico, concentraciones elevadas de esas citosinas pueden estar relacionadas a la elevaci&#243;n en las concentraciones plasm&#225;ticas de insulina, a las anormalidades en el metabolismo de las hormonas esteroideas, a la hormona del crecimiento<sup>39</sup>, a la disfunci&#243;n del ventr&#237;culo izquierdo<sup>5</sup> y a la intolerancia al ejercicio<sup>3,7,40</sup>.</p>
      <p>Sin embargo, poco se sabe respecto a los mecanismos responsables de la inducci&#243;n de ese aumento en la producci&#243;n de TNF-&#945;, y as&#237;, algunas hip&#243;tesis se vienen proponiendo (<xref ref-type="fig" rid="f1-body2">Figura 1</xref>). Conocidamente, monocitos y macr&#243;fagos activados son la principal fuente de TNF-&#945;<sup>23</sup>, siendo que, un aumento en la producci&#243;n de prostaglandina E<sub>2</sub>, observado en pacientes con IC, podr&#237;a estimular macr&#243;fagos a producir TNF-&#945;<sup>38</sup>. Estudios anteriores<sup>41</sup> demostraron que macr&#243;fagos de la cavidad peritoneal, en ratones con IC inducida por IM, presentan aumento en la producci&#243;n de TNF-&#945;, entre otras citosinas proinflamatorias (IL-1&#946; e IL-6), cuando estimulados con LPS.</p>
      <fig id="f1-body2">
        <graphic xlink:href="1678-4170-abc-93-06-0692-00021-gf01-es.jpg"/></fig>
      <p>Por otra parte, evidencias recientes han sugerido que en la IC, el TNF-&#945; estar&#237;a alterado independientemente del cuadro inflamatorio y de la causa de la enfermedad, sugiriendo que el aumento de esa citosina est&#233; m&#225;s asociado a la presencia de las limitaciones impuestas por la IC, en vez de que sea ella la causadora de ese cuadro<sup>6,42</sup>. As&#237;, en la IC, los mecanismos moduladores de la producci&#243;n de TNF-&#945; son poco comprendidos, y, por otra parte, esa citosina parece tener un rol complejo siendo un "eslab&#243;n" de la comunicaci&#243;n entre varios sistemas regulatorios<sup>5,38</sup>.</p>
      <p>
        <bold>Rol del IL-10 en la progresi&#243;n de la IC</bold>
      </p>
      <p>Debido al gran n&#250;mero de estudios que relacionaron el rol de las citosinas proinflamatorias con la patogenia y la progresi&#243;n de la IC, en consecuencia a esta, se viene especulando la posibilidad de intervenciones con la manipulaci&#243;n de citosinas antiinflamatorias como adyuvantes en las terapias en pacientes con IC. Por otra parte, a pesar de ese potencial terap&#233;utico, solo recientemente se ha enfocado el rol de la IL-10 en la IC<sup>14,43</sup>.</p>
      <p>La interleuquina 10 (IL-10) es un polipept&#237;dico homodim&#233;rico de 17 kDa, que inicialmente se describi&#243; como un factor producido por linfocitos T auxiliadores (tipo 2) con propiedades inhibitorias en clones de linfocitos T auxiliadores (tipo 1), sobre todo en la respuesta proliferativa y en la producci&#243;n de citosinas<sup>21</sup>. Esa citosina se produce por una serie de diferentes tipos celulares, en especial las c&#233;lulas inflamatorias como macr&#243;fagos y linfocitos T, donde es el principal inhibidor de la s&#237;ntesis de citosinas y de la actividad funcional de macr&#243;fagos, bien como inhibe la producci&#243;n, tanto de las citosinas proinflamatorias, como de las metaloproteinasas de la matriz extracelular<sup>8,21</sup>.</p>
      <p>Su actividad biol&#243;gica se intermedia a trav&#233;s de su receptor de membrana (IL-10R), que pertenece al subgrupo de receptores similares al interfer&#243;n (INF), de la familia de los receptores de citosinas clase II<sup>21,22</sup>. De esa forma, la IL-10 puede inhibir la producci&#243;n de varias citosinas, tales como TNF-&#945;, IL-1&#946; y IL-6, en una variedad de tipos celulares, adem&#225;s de automodularse<sup>15,21</sup>. Tambi&#233;n inhibe la generaci&#243;n de especies reactivas del ox&#237;geno (intermediarios) y aumenta la liberaci&#243;n de los receptores RsTNF, que pueden antagonizar los efectos del TNF-&#945;<sup>44</sup>. Adem&#225;s, estudios est&#225;n revelando que la IL-10 tiene su producci&#243;n aumentada en procesos inflamatorios, como en la anemia y en la artritis reumatoide, adem&#225;s de la IC, ejerciendo una funci&#243;n predominantemente inmunomoduladora en esas condiciones<sup>15</sup>.</p>
      <p>Bolger et al.<sup>45</sup> demostraron que la IL-10 inhibe la secreci&#243;n de TNF-&#945; en c&#233;lulas mononucleares de la sangre perif&#233;rica aislada (<italic>ex vivo</italic>) de pacientes con IC (clase funcional III, NYHA). En otro estado inflamatorio cr&#243;nico -como la aterosclerosis- en ratones (C57BL/6J, <italic>knockout</italic> para IL-10) la IL-10 tambi&#233;n se viene describiendo por sus propiedades protectoras (antiinflamatoria) en retardar la progresi&#243;n de la enfermedad, una vez que altos niveles de IL-10 se asociaron con la disminuci&#243;n de apoptosis y de la expresi&#243;n de mRNA de la &#237;ONS-1 en las c&#233;lulas endoteliales, macr&#243;fagos y linfocitos T de esos animales<sup>46</sup>.</p>
      <p>As&#237; como ha sido muy bien descrito anteriormente, la IL-10 act&#250;a predominantemente de manera antiinflamatoria y modulatoria en la respuesta inflamatoria, condici&#243;n que parece ser a&#250;n m&#225;s evidente en condiciones (enfermedades) inflamatorias cr&#243;nicas, sobre todo en aquellas en que el TNF-&#945; parece actuar de manera significativa (ej.: artritis reumatoide, esclerosis m&#250;ltiple, enfermedad inflamatoria del aparato digestivo, IC, entre otras)<sup>45,47,48</sup>. De ese modo, el estudio de Gullestand et al.<sup>43</sup> demostr&#243; que la infusi&#243;n intravenosa de inmunoglobulina -terapia utilizada en enfermedades mediadas por el sistema inmune, tales como el s&#237;ndrome de Kawasaki, la dematomiositis y la esclerosis m&#250;ltiple- en pacientes con IC (cardiomiopat&#237;a dilatada y enfermedad isqu&#233;mica del miocardio) aument&#243; los niveles de IL-10. Adem&#225;s, ese aumento present&#243; una correlaci&#243;n positiva con la mejora en la fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo en pacientes con IC, as&#237; como en animales con IC inducida por IM. La relaci&#243;n de la producci&#243;n de la IL-10 por el TNF-&#945; (tasa IL-10/ TNF-&#945;) en el ventr&#237;culo izquierdo demostr&#243; ser un indicador todav&#237;a m&#225;s preciso del grado de disfunci&#243;n ventricular en esa condici&#243;n<sup>48</sup>.</p>
      <p>Recientemente, el estudio de Yu et al.<sup>49</sup>, demostr&#243; que manifestaciones perif&#233;ricas de IC inducida por IM en ratones, pueden atenuarse por la reducci&#243;n de la intensidad de la respuesta inflamatoria/inmune en el cerebro. En esos animales, la alteraci&#243;n en el balance de las citosinas pro y antiinflamatorias inducidas por la administraci&#243;n de un vector adenoviral codificador del gen para IL-10 humano, logr&#243; efectos "ben&#233;ficos" en los &#237;ndices de severidad de la IC, tales como mejora en la funci&#243;n del ventr&#237;culo izquierdo y disminuci&#243;n de los niveles de noradrenalina plasm&#225;tica, adem&#225;s de menor prominencia en el remodelaci&#243;n del ventr&#237;culo derecho y en la congesti&#243;n vascular pulmonar. Otro estudio, que administr&#243; <italic>in vivo</italic> la rhIL-10, demostr&#243; el mismo efecto<sup>45</sup>. Todav&#237;a en ese aspecto, Yamaoka et al.<sup>15</sup> demostraron que leucocitos mononucleares recolectados de pacientes con IC (clase funcional II-IV, NYHA) presentaron aumento de los receptores de IL-10 en la membrana celular de estas.</p>
      <p>Tomados en conjunto, esos estudios sugieren un papel de suma importancia de la IL-10 en la fisiopatolog&#237;a de IC, sobre todo debido a su efecto modulador de la s&#237;ntesis y secreci&#243;n del TNF-&#945;. As&#237;, esa citosina viene ganando un rol importante como posibilidad terap&#233;utica. A&#250;n en ese aspecto, la tasa IL-10/ TNF-&#945; puede tener un rol aditivo en la evaluaci&#243;n del deterioro y progresi&#243;n del cuadro de la IC, y, por otra parte, m&#225;s estudios son necesarios para la comprensi&#243;n de los mecanismos moleculares que modulan los eventos citados anteriormente.</p>
      <p>
        <bold>Efecto del entrenamiento aerobio en las citosinas proinflamatorias en la IC</bold>
      </p>
      <p>Es muy evidente actualmente que el entrenamiento f&#237;sico est&#225; directamente asociado a la mejora funcional de las capacidades f&#237;sicas condicionales, como en el VO<sub>2pico</sub>, en la funci&#243;n endotelial y en consecuencia, en la calidad de vida en pacientes con IC<sup>11,50-52</sup>. Otras variables asociadas a un pron&#243;stico peor, tales como mejora en la actividad simp&#225;tica y neurohormonal y en la hipoxia perif&#233;rica, tambi&#233;n se est&#225;n relatando como moduladas positivamente por el entrenamiento f&#237;sico<sup>53</sup>. Otro aspecto que todav&#237;a hay que destacar es el efecto directo en la reducci&#243;n en la frecuencia cardiaca subm&#225;xima (durante el ejercicio f&#237;sico) y en reposo<sup>50</sup>. En consecuencia, las directrices m&#233;dicas<sup>1,18</sup> recomiendan el entrenamiento f&#237;sico como un componente terap&#233;utico en programas de rehabilitaci&#243;n para pacientes con IC controlada.</p>
      <p>Adem&#225;s de los beneficios ya mencionados, recientemente, Adamapoulus et al.<sup>54</sup> demostraron una reducci&#243;n en la concentraci&#243;n plasm&#225;tica de marcadores inflamatorios perif&#233;ricos (mol&#233;cula soluble de adhesi&#243;n celular-1, mol&#233;cula soluble de c&#233;lula vascular-1 y prote&#237;na quimioatractante para macr&#243;fagos-1) tras 12 semanas de entrenamiento aerobio en cicloerg&#243;metro ( al 70-80% FC<sub>max</sub>), cinco veces por semana durante una hora por d&#237;a, en pacientes con IC moderada a severa (NYHA, clase funcional II - III), sugiriendo una correlaci&#243;n entre la mejora en la tolerancia al ejercicio y la atenuaci&#243;n del proceso inflamatorio, debido a una posible reversi&#243;n de los efectos delet&#233;reos causados por la disfunci&#243;n endotelial presentada en el cuadro de IC. As&#237;, Batista et al.<sup>20</sup> demostraron en ratones Wistar con IC inducida por infarto agudo del miocardio, tras el empleo de un programa de entrenamiento aerobio moderado (carrera en la estera) con duraci&#243;n de 10 semanas, la reversi&#243;n de algunos par&#225;metros inflamatorios en macr&#243;fagos peritoneales y linfonodos mesent&#233;ricos, alcanzando valores pr&#243;ximos a los encontrados en los grupos controles. Sin embargo, la evidencia de la correlaci&#243;n significativa no puede establecer una relaci&#243;n de causa-efecto, y se vienen proponiendo otros mecanismos para explicar los efectos "ben&#233;ficos" mediados por el entrenamiento f&#237;sico en individuos portadores de IC.</p>
      <p>La reducci&#243;n en la concentraci&#243;n plasm&#225;tica de TNF-&#945;, IL-6 y sus respectivos receptores en la forma soluble se est&#225; evidenciando asimismo en individuos con IC sometidos a un programa de entrenamiento aerobio<sup>55</sup>, sugiriendo una atenuaci&#243;n en el cuadro inflamatorio cr&#243;nico, mediada por una regulaci&#243;n en la respuesta inflamatoria perif&#233;rica<sup>56,57</sup>. Sin embargo, a pesar de haber sido caracterizado el efecto restaurador y/o antiinflamatorio del ejercicio en esas condiciones, poco se sabe respecto a los posibles mecanismos por los cuales el entrenamiento aerobio puede modular ese proceso<sup>57</sup>.</p>
      <p>Siguiendo esa l&#237;nea de razonamiento, Gielen et al.<sup>58</sup> publicaron el primer estudio que demostr&#243; el aumento en la expresi&#243;n local de citosinas proinflamatorias, en muestras provenientes de biopsia del m&#250;sculo esquel&#233;tico en individuos con IC. Por otra parte, no se demostr&#243; ese aumento cuando el par&#225;metro evaluado fue la concentraci&#243;n plasm&#225;tica de esas citosinas y, as&#237;, se est&#225; especulando que la inflamaci&#243;n local preceder&#237;a las alteraciones plasm&#225;ticas detectadas. A&#250;n en ese estudio, la utilizaci&#243;n del entrenamiento aerobio en estera ergom&#233;trica al 70% VO<sub>2pico</sub>, durante seis meses, fue capaz de atenuar esa expresi&#243;n local aumentada, una vez que demostr&#243; que esa reducci&#243;n se asoci&#243; a la reducci&#243;n en la expresi&#243;n del gen de la &#237;ONS y al acumulaci&#243;n intracelular de NO, sugiriendo entonces que la utilizaci&#243;n del entrenamiento f&#237;sico debe ocurrir no solo como una forma de intervenci&#243;n que objetiva la mejora de las capacidades f&#237;sicas (comprometidas o no por el IC), sino como una estrategia terap&#233;utica con finalidad antiinflamatoria local.</p>
      <p>No obstante, recientemente, el mismo grupo de autores demostr&#243; que el efecto antiinflamatorio inducido por el entrenamiento aerobio en la expresi&#243;n y producci&#243;n de las citosinas (TNF-&#945;, IL-1&#946;, IL-6) y de la &#237;ONS, que se correlacionaron a la mejora en la actividad m&#225;xima de la enzima citocromo <italic>c</italic> oxidasa (COX) y en el VO<sub>2pico</sub> , sugiere que la mejora en los par&#225;metros inflamatorios ocurrieron en funci&#243;n de una mejora en el metabolismo oxidativo del m&#250;sculo esquel&#233;tico en pacientes con IC<sup>11</sup>.</p>
      <p>La reducci&#243;n en la concentraci&#243;n plasm&#225;tica de TNF-&#945;, IL-6 y sus respectivos receptores en la forma soluble tambi&#233;n se han demostrado en individuos con IC sometidos a un programa de entrenamiento aerobio<sup>55</sup>, sugiriendo una atenuaci&#243;n en el cuadro inflamatorio cr&#243;nico, mediada por una regulaci&#243;n en la respuesta inflamatoria perif&#233;rica<sup>54,55</sup>. De la misma forma, la utilizaci&#243;n de un programa de cuatro meses de entrenamiento f&#237;sico con ejercicios aerobios en cicloerg&#243;metro (el 90% liminar anaer&#243;bico-I), tres veces por semana, durante 20 minutos, en conjunto con ejercicios resistidos (el 50% RM y nueve ejercicios por sesi&#243;n), durante 30 minutos, present&#243; una reducci&#243;n en la concentraci&#243;n de sTNFR I y II en pacientes con IC, sugiriendo un posible efecto de los ejercicios aerobios utilizados simult&#225;neamente a los resistidos en la atenuaci&#243;n del cuadro inflamatorio<sup>56</sup>.</p>
      <p>En esa condici&#243;n, las evidencias cient&#237;ficas acumuladas recientemente sugieren que mediadores inflamatorios, como las citosinas proinflamatorias, tienen un rol importante, tanto en la patogenia, como en el desarrollo del s&#237;ndrome de la IC. As&#237;, programas de entrenamiento f&#237;sico moderado, con duraci&#243;n de tres a seis meses, tres a cinco sesiones por semana, durante una hora, adem&#225;s de que ejercen un efecto positivo en las variables cardiocirculatorias, ya bien establecido en la literatura, act&#250;an como un importante inmunomodulador positivo, revertiendo, aunque de manera parcial, las alteraciones inflamatorias originadas del cuadro de IC, reforzando su rol de intervenci&#243;n no farmacol&#243;gica.</p>
      <p>
        <bold>Rol del entrenamiento f&#237;sico como estrategia antiinflamatoria</bold>
      </p>
      <p>En los &#250;ltimos a&#241;os, varios estudios han propuesto que el ejercicio f&#237;sico (sesi&#243;n aguda) ejerce una acci&#243;n antiinflamatoria, especialmente tras la realizaci&#243;n de este, y a su vez, la principal citosina involucrada en esa modulaci&#243;n es la IL-6<sup>59,60</sup>. Ese efecto antiinflamatorio es caracterizado por el aumento plasm&#225;tico, subsiguiente, de las citosinas IL-10, ILra y de los receptores solubles del NF I y II, inducidas por la IL-6, tras una sesi&#243;n de ejercicio f&#237;sico<sup>60</sup>. Todav&#237;a, este efecto se viene revelando m&#225;s evidente en algunos cuadros patol&#243;gicos, como aterosclerosis, diabetis tipo II, obesidad y IC, sobre todo aquellos que presentan un cuadro caracterizado como inflamaci&#243;n sist&#233;mica cr&#243;nica de baja intensidad (del ingl&#233;s <italic>low grade chronic inflammation</italic>), condici&#243;n caracterizada por el aumento sist&#233;mico de dos a tres veces en los niveles de citosinas proinflamatorias y prote&#237;na C reactiva<sup>61</sup> (<xref ref-type="fig" rid="f2-body2">figura 2</xref>).</p>
      <fig id="f2-body2">
        <graphic xlink:href="1678-4170-abc-93-06-0692-00021-gf02-es.jpg"/></fig>
      <p>Adem&#225;s, este perfil de producci&#243;n de las citosinas que ocurre durante e inmediatamente tras la realizaci&#243;n del ejercicio f&#237;sico depende de varios factores, tales como poblaci&#243;n (sedentarios, presencia o no de enfermedades, etc.); intensidad o duraci&#243;n del ejercicio f&#237;sico; disponibilidad de glucosa; y tiempo de recolecci&#243;n de las muestras<sup>62</sup>.</p>
      <p>Dada esta condici&#243;n, la hip&#243;tesis que se viene proponiendo es que la pr&#225;ctica regular de ejercicio f&#237;sico, organizado en un programa de entrenamiento, ejerce un efecto antiinflamatorio inducido por las varias sesiones agudas, que conducir&#237;a a una protecci&#243;n contra situaciones inflamatorias cr&#243;nicas, especialmente por la reducci&#243;n de los niveles de citosinas proinflamatorias y prote&#237;na C reactiva<sup>60,63</sup>. A pesar de la evidente correlacci&#243;n, poca informaci&#243;n se est&#225; produciendo hasta el momento, respecto a los posibles mecanismos que culminan en la relaci&#243;n causa-efecto del entrenamiento f&#237;sico y en la reducci&#243;n de esos marcadores<sup>59</sup>. A&#250;n en esos cuadros, el origen de esa alteraci&#243;n sist&#233;mica no est&#225; bien caracterizada, pero, se viene proponiendo que el tejido adiposo blanco<sup>60</sup> y las c&#233;lulas mononucleares de la sangre perif&#233;rica (en especial los linfocitos) pueden ser la principal fuente de esas citosinas<sup>59,63</sup>.</p>
      <p>Para evaluar ese posible efecto antiinflamatorio, Starkie et al.<sup>64</sup> demostraron, en un modelo experimental de inflamaci&#243;n sist&#233;mica de baja intensidad, que se indujo a trav&#233;s de la administraci&#243;n venosa de endotoxina (<italic>Escherichia coli</italic>) en individuos sanos, despu&#233;s de tres horas de la realizaci&#243;n de una sesi&#243;n de ejercicio aerobio en cicloerg&#243;metro ( al 75 % del VO<sub>2pico</sub>), una reducci&#243;n en los niveles de TNF-&#945; inducido por el modelo experimental. Ese mismo efecto supresor inducido por el ejercicio f&#237;sico, tambi&#233;n se demostr&#243; en ratones <italic>knockout</italic> para los receptores de TNF-&#945; tipo I y II, restaurando los niveles aumentados de TNF-&#945;<sup>65</sup>. No obstante, los posibles mecanismos moduladores de este efecto "ben&#233;fico" no est&#233;n establecidos.</p>
      <p>
        <bold>Posibles mecanismos involucrados en la resposta antiinflamatoria tras el ejercicio f&#237;sico</bold>
      </p>
      <p>Pese a que en los &#250;ltimos a&#241;os se ha evidenciado la importancia de los mediadores proinflamatorios en la patogenia de la IC, solo recientemente se observ&#243; que esta se sigui&#243; de un aumento correspondiente en las citosinas antiinflamatorias, tales como la IL-10, y del factor de transformaci&#243;n del crecimiento (TGF), resultando en un desequilibrio en el balance de citosinas (pro vs antiinflamatorias).</p>
      <p>La terap&#233;utica farmacol&#243;gica convencionalmente utilizada en la IC con impacto en la mortalidad (ex: &#946;-bloqueantes, inhibidores de la enzima conversora de angiotensina y espironolactona) viene evidenciando un efecto discreto en la reducci&#243;n de marcadores inflamatorios en esos pacientes, y as&#237;, se est&#225; proponiendo y probada la terapia inmunomodulatoria en combinaci&#243;n al tratamiento convencional como una opci&#243;n adyuvante<sup>66</sup>. Teniendo en cuenta esta condici&#243;n, la terap&#233;utica adyuvante (ex: pentoxifilina, inmunoglobulina intravenosa, talidomina, infliximab y las estatinas) vienen demostrado resultados prometedores en peque&#241;os estudios, pero, solo en lo que se refiere a desenlaces de menor relevancia cl&#237;nica, como por ejemplo, la mejora del perfil bioqu&#237;mico<sup>66</sup>. Tradicionalmente, se excluyen pacientes con IC de los estudios en que se comprueban los efectos de las estatinas en eventos cl&#237;nicos. Sin embargo, recientemente, un estudio<sup>67</sup> evalu&#243; el efecto de la estatina (rosuvastatina) en pacientes con m&#225;s de 60 a&#241;os de edad y con insuficiencia cardiaca sist&#243;lica moderada a severa. En ese estudio, el uso de 10mg/d&#237;a de rosuvastatina tuvo un efecto estad&#237;sticamente significante en la reducci&#243;n de los niveles de LDL-colesterol y marcadores inflamatorios como la prote&#237;na C reactiva.</p>
      <p>En ese aspecto, como ya se ha descrito con anterioridad, la utilizaci&#243;n del entrenamiento f&#237;sico como terap&#233;utica adyuvante se ha mostrado, adem&#225;s de restaurador de las funciones cardiovasculares ocurridas a causa de la IC (que parece no ocurrir en las terap&#233;uticas adyuvantes arriba citadas), un importante agente inmunomodulador. Por otra parte, a pesar del aumento de evidencias que demuestran la importancia de la IL-10, sobre todo debido a su acci&#243;n antiinflamatoria, y hasta donde sabemos, pocos son los estudios que evaluaron los posibles efectos del entrenamiento f&#237;sico en modular la producci&#243;n local de IL-10, que tiene un papel importante en el balance pro/antiinflamatorio, sobre todo en condiciones en que hay un desequilibrio en esa relaci&#243;n.</p>
      <p>Teniendo en cuenta esta condici&#243;n, la hip&#243;tesis que se est&#225; proponiendo es que la pr&#225;ctica regular de ejercicio f&#237;sico, organizado en un programa de entrenamiento, ejerce un efecto antiinflamatorio inducido por las varias sesiones agudas, que conducir&#237;a a una protecci&#243;n contra situaciones inflamatorias cr&#243;nicas, especialmente por la reducci&#243;n de los niveles de citosinas proinflamatorias y prote&#237;na C reactiva<sup>60,63</sup>. Sin embargo, los posibles mecanismos moduladores de ese efecto "ben&#233;fico" no est&#225;n establecidos, y podr&#237;an estar relacionados tanto a la mejora en las capacidades f&#237;sicas condicionales como al efecto antiinflamatorio directo.</p>
      <p>Como ya se ha descrito, la IL-10 modula procesos inflamatorios a trav&#233;s de la supresi&#243;n de la producci&#243;n de citosinas proinflamatorias, en especial el TNF-&#945;, que es transcricionalmente modulado por el sistema NF-&#954;B. Adem&#225;s, un estudio reciente demostr&#243; que, en ratones, el entrenamiento aerobio en estera ergom&#233;trica aumenta la activaci&#243;n de ese sistema, especialmente v&#237;a reducci&#243;n de los niveles de I&#954;B&#945; (prote&#237;na inhibitoria del sistema NF-&#954;B) y aumento en la fosforilaci&#243;n de la IKK (enzima que degrada el complejo proteico I&#954;B)<sup>68</sup>. Vale todav&#237;a destacar en este punto que, a pesar de que las evidencias demuestren que la IL-10 inhibe una serie de alteraciones mediadas por el TNF-&#945;, sobre todo aqu&#233;llos que involucran la activaci&#243;n del factor de transcripci&#243;n NF-&#954;B, y que el entrenamiento aerobio aumenta la activaci&#243;n de ese sistema, hasta el presente momento, ninguno de esos estudios ha evaluado el efecto del entrenamiento en una condici&#243;n en que hubiera la activaci&#243;n del sistema NF-&#954;B, como la IC. Por otra parte, en pacientes con diabetes tipo II, el programa de entrenamiento aerobio en bicicleta ergom&#233;trica ( al 70% VO<sub>2pico</sub>, cuatro veces por semana, durante ocho semanas) demostr&#243; un aumento en el nivel proteico de la I&#954;B&#945; y &#946; en ambos los individuos (diab&#233;ticos y control de la misma edad) que se sigui&#243; de una reducci&#243;n de los niveles proteicos del TNF-&#945;<sup>69</sup>. As&#237;, los probables mecanismos respecto al posible efecto del entrenamiento f&#237;sico en la IC, en modular la producci&#243;n de TNF-&#945; a trav&#233;s del aumento de la IL-10 est&#225;n detallados en la <xref ref-type="fig" rid="f3-body2">Figura 3</xref>.</p>
      <fig id="f3-body2">
        <graphic xlink:href="1678-4170-abc-93-06-0692-00021-gf03-es.jpg"/></fig>
      <p>
        <bold>Consideraciones Finales</bold>
      </p>
      <p>Dado lo expuesto, datos provenientes de la literatura especializada corroboran la hip&#243;tesis antiinflamatoria. Especialmente, la prote&#237;na IL-10 parece ser afectada por el entrenamiento f&#237;sico (sobre todo aerobio), pudiendo actuar como un importante "gatillo" en la atenuaci&#243;n y/o modulaci&#243;n de la respuesta inflamatoria en la IC. Todav&#237;a, adem&#225;s del aumento local en la producci&#243;n de IL-10, inducido por el entrenamiento f&#237;sico, ese efecto podr&#237;a tener impacto sist&#233;mico, reduciendo, o hasta mismo evitando el aumento en los niveles plasm&#225;ticos de las citosinas proinflamatorias, condici&#243;n que, en el caso de la IC est&#225; relacionada a la mayor severidad de esa enfermedad. Estudios evaluando el efecto del entrenamiento f&#237;sico controlado en desenlaces cl&#237;nicos relevantes, como mortalidad en pacientes con IC, son necesarios para que esa modalidad terap&#233;utica pueda eventualmente incorporarse a la pr&#225;ctica cl&#237;nica.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de la tesis de Doctorado de Miguel Luiz Batista J&#250;nior del Departamento de Biolog&#237;a Celular y de Desarrollo del Instituto de Ciencias Biom&#233;dicas - USP.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Anti-inflammatory effect of physical training in heart failure: role of TNF-&#945; and IL-10</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>Over the past 50 years, the understanding of the deteriorative changes involved in the progression of heart failure (HF), initially described as resulting from changes in salt and fluid retention, or changes in hemodynamic parameters, have changed significantly. Recently, several studies conducted in HF patients showed altered plasma (or serum) levels of pro-inflammatory cytokines, such as tumor necrosis factor &#945; (TNF-&#945;), interleukins 1, 6, and 18, and cardiotropin-1, among other inflammatory markers. These changes were independent of HF etiology, suggesting a common pathogenic pathway. In response to these new findings, interventions to prevent and/or reduce these inflammatory changes have been proposed. The aerobic training-induced cardiovascular benefits of physical exercises performed at intensities ranging from mild to moderate have been previously reported. Moreover, it has been shown that moderate aerobic physical training seems to be able to modulate, in the presence of an abnormal chronic inflammatory condition, the overexpression of pro-inflammatory cytokines, soluble adhesion molecules, chemoattractant factors and oxidative stress. Altogether, these data indicate a possible anti-inflammatory effect induced by physical training. Therefore, this review aims to assess the role of physical training as an alternative non-pharmacological adjuvant to be administered in some pathological conditions in which TNF-&#945; chronic changes are predominant, as in HF. The "anti-inflammatory effect" induced by physical training seems to be primarily mediated by IL-10.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Exercise</kwd>
        <kwd>heart failure</kwd>
        <kwd>coronary artery disease</kwd>
        <kwd>interleukins</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>REVIEW ARTICLE</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Anti-inflammatory effect of physical training in heart failure: role of TNF-</bold>
          </label>
          <p>
            <bold>&#945; and IL-10</bold>
          </p>
        </fn>
      </p>
      <p>
        <bold>Miguel Luiz Batista J&#250;nior<sup>I</sup>; Renato Delascio Lopes<sup>II, III</sup>; Mar&#237;lia Cerqueira Leite Seelaender<sup>I</sup>; Antonio Carlos Lopes<sup>II</sup></bold>
      </p>
      <p><sup>I</sup>Grupo de Biologia Molecular da C&#233;lula - Instituto de Ci&#234;ncias Biom&#233;dicas I e Departamento de Medicina Interna - Universidade Federal de S&#227;o Paulo, SP</p>
      <p><sup>II</sup>Departamento de Medicina Interna, Universidade Federal de S&#227;o Paulo, SP - Brazil</p>
      <p><sup>III</sup>Duke Clinical Research Institute, Durham- North Caroline - USA</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p>Over the past 50 years, the understanding of the deteriorative changes involved in the progression of heart failure (HF), initially described as resulting from changes in salt and fluid retention, or changes in hemodynamic parameters, have changed significantly. Recently, several studies conducted in HF patients showed altered plasma (or serum) levels of pro-inflammatory cytokines, such as tumor necrosis factor &#945; (TNF-&#945;), interleukins 1, 6, and 18, and cardiotropin-1, among other inflammatory markers. These changes were independent of HF etiology, suggesting a common pathogenic pathway. In response to these new findings, interventions to prevent and/or reduce these inflammatory changes have been proposed.</p>
      <p> The aerobic training-induced cardiovascular benefits of physical exercises performed at intensities ranging from mild to moderate have been previously reported. Moreover, it has been shown that moderate aerobic physical training seems to be able to modulate, in the presence of an abnormal chronic inflammatory condition, the overexpression of pro-inflammatory cytokines, soluble adhesion molecules, chemoattractant factors and oxidative stress. Altogether, these data indicate a possible anti-inflammatory effect induced by physical training.</p>
      <p> Therefore, this review aims to assess the role of physical training as an alternative non-pharmacological adjuvant to be administered in some pathological conditions in which TNF-&#945; chronic changes are predominant, as in HF. The "anti-inflammatory effect" induced by physical training seems to be primarily mediated by IL-10.</p>
      <p><bold>Key words:</bold> Exercise; heart failure; coronary artery disease; interleukins.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Heart failure (HF) is a clinical syndrome of complex pathophysiology, which may be due to any structural or functional disorder that affects the heart, and consequently undermines the ability of the ventricles to fill up and pump blood adequately<sup>1,2</sup>. Dyspnea and fatigue are cardinal manifestations of HF which may limit the ability of the patient to perform physical exercise (exercise intolerance) and can lead to processes that may result in systemic pulmonary congestion and increased peripheral vascular resistance<sup>1,3,4</sup>. The main cardiac causes of HF are coronary artery diseases, including hypertension, dilated cardiomyopathies and heart valve diseases<sup>1,2</sup>.</p>
      <p>Currently, the deteriorative changes involved in the progression of HF, which were previously interpreted as arising from changes in salt and water retention or changes in hemodynamic parameters, have been described as recurring processes that culminate in local and systemic inflammatory activation<sup>5-9</sup>, which can be evidenced by the increase in the gene expression and the production of proinflammatory cytokines, such as tumor necrosis factor &#945; (TNF-&#945;); interleukins 1&#946; (IL-1&#946;), 6 (IL-6) and 18 (IL-18 ); cardiotropin-1; CC and CXC chemokines, among other inflammatory markers, in plasma, muscle-skeletal and heart, as well as in peripheral lymphocytes of rats and HF patients. In addition to contributing to the pathophysiology and the progression of structural and functional changes in the heart muscle, these inflammatory mediators may directly lead to peripheral manifestations of the HF syndrome, especially in those changes related to a decrease in muscle mass and functional changes<sup>10,11</sup>, among others.</p>
      <p>Following this line of reasoning, Coats et al<sup>7</sup> proposed a hypothesis called "the muscle hypothesis of HF", according to which the degenerative changes are due to a reduced perfusion in skeletal muscles caused by low cardiac output, resulting in tissue hypoxia. If maintained for a long time, this tissue hypoxia and the consequent increase in the production of free radicals are a powerful stimulus for the production of pro-inflammatory cytokines (TNF-&#945;, IL-1 &#946; and IL-6), mediated by nuclear factor kappa-light-chain-enhancer of activated B cells (NF-&#186;B), initiating a cascade of events which comprises the expression of inducible nitric oxide synthase (iNOS), skeletal muscle apoptosis and loss of muscle mass<sup>5,11-13</sup>.</p>
      <p>Therefore, although in recent years most studies have focused on the HF pro-inflammatory cytokines, today the anti-inflammatory cytokines, particularly IL-10, have gained prominence and may have an important role in the pathophysiology of HF<sup>14,15</sup>. In patients with HF, a decrease in IL-10 plasma concentration has been reported and positively correlated with a decrease in the left ventricular ejection fraction<sup>16</sup>. Furthermore, in animals with myocardial infarction-induced HF, the use of the rate of production of IL-10 by TNF- &#945; (IL-10 / TNF- &#945; rate) has recently been demonstrated as a more accurate indicator of the degree of ventricular dysfunction in that condition<sup>14,17</sup>.</p>
      <p>Physical training, carried out mainly through aerobic exercises, has been considered as the main basis for cardiac rehabilitation programs and an important form of non-pharmacological treatment, which can achieve the established goal of minimizing the risk factors that predispose the individual to cardiovascular diseases<sup>18,19</sup>.</p>
      <p>Besides the cardiovascular benefits, induced both by changes in the function of the heart as a pump and by peripheral changes, physical training seems to be able to modulate, in the presence of an abnormal chronic inflammatory condition, the expression of pro-inflammatory cytokines, soluble adhesion molecules and chemoattractant factors<sup>8,20</sup>. The use of aerobic training on an ergometric treadmill at 70% VO<sub>2peak</sub> for six months was able to diminish the increased local expression of pro-inflammatory cytokines (TNF-&#945;, IL-1&#946;, IL-6) in striated skeletal muscle in patients with HF. In the same study, it was shown that this reduction was associated with a reduction in the gene expression of iNOS and the accumulation of intracellular nitric oxide (NO), suggesting that physical training should be used not only as a form of intervention to improve physical capacity (affected or not by HF), but as a therapeutic strategy with local anti-inflammatory purposes.</p>
      <p>In this regard, several studies have shown changes in plasma concentration of IL-10 and IL-ra (IL-1 receptor antagonist) after exercise, a condition which can contribute to the anti-inflammatory milieu, and thus be an important mediator of the anti-inflammatory effects of physical training. IL-10 can act in different cell types and induces suppression of inflammatory response in several cell types<sup>21</sup>. Moreover, this cytokine has been postulated as the main molecule responsible for the "orchestra" of inflammatory reactions, especially the inhibition of the changes mediated by TNF- &#945; <sup>21,22</sup>.</p>
      <p>Moreover, despite increasing evidence indicating the existence of a relationship between the anti-inflammatory effect of exercise and its protective and/or inhibitor effect in various clinical pictures, possible long range effects (training) are not well characterized.</p>
      <p>Therefore, we may conclude that only recently the possible anti-inflammatory effects of physical training on the production of pro-inflammatory (TNF-&#945;) and anti-inflammatory (IL-10) cytokines in patients with HF have been studied. On the other hand, adaptations resulting from moderate aerobic training (55% - 65% VO<sub>2peak</sub>) may have immunomodulatory effects, especially in the production of IL-10, a condition that could be even more evident in clinical pictures that present a chronic increase in the production of these inflammatory markers. Besides, increased physical activity is critical in the adjuvant treatment of patients with HF, depending, of course, on the intensity of this reduction in the severity of the disease.</p>
      <p>
        <bold>Role of TNF-</bold>
        <bold>&#945; in the progression of HF</bold>
      </p>
      <p>As described above, pro-inflammatory cytokines, especially TNF-&#945;, and other inflammatory mediators such as chemokines, play a prominent role in several levels of HF. Initially, although their release has a restoration or repair function, if maintained over time they can have an important role in the modulation of the deteriorating changes of HF<sup>23</sup>. These data are corroborated by other model studies data in which high levels of inflammatory mediators, such as TNF-&#945; and nitric oxide, were experimentally induced to mimic some characteristic clinical changes of HF, such as progressive left ventricular dysfunction, pulmonary edema and cardiomyopathies<sup>24</sup>. Moreover, several changes detected in plasma levels show a correlation with markers of characteristic dysfunctions of HF, which are also prognostic and severity markers of HF<sup>25,26</sup>.</p>
      <p>Besides the changes in plasma levels, a recent study<sup>27</sup> showed positive correlations between TNF-&#945; levels in the cardiac myocyte and in the hypothalamic paraventricular nucleus in rats with HF. In addition, these changes were related to a higher neurohumoral excitation in the brain cardiovascular region<sup>28</sup> and greater activation of the renin-angiotensin system<sup>29</sup>, suggesting a possible interaction between these systems (renin-angiotensin system and immune system) which may modulate changes such as sodium and water retention and the cardiac remodeling process in rats with HF.</p>
      <p>TNF-&#945; was described in 1975 and it was initially named cachectin due to its potent cytotoxic effect against tumor cells<sup>23,25</sup>. It is a trimeric polypeptide (17 kDa), produced mainly by activated monocytes and macrophages, and other cells, such as lymphocytes, fibroblasts, neutrophils, smooth muscle cells and mastocytes<sup>23,30</sup>. This cytokine can act in almost all types of nucleated cells by two types of membrane receptors, type I (TNFR-I, p55) and type II (TNFR-II, p75), or as a soluble molecule, both biologically active<sup>8,23</sup>.</p>
      <p>Previous studies demonstrated the presence of both types of receptors, in the skeletal muscle<sup>31</sup> and in the heart muscle<sup>8</sup>. After translation, similarly to TNF-&#945;, both receptors are inserted into the cell membrane. In the proteolytic cleavage, mediated by a TNF-&#945; converting metalloproteinase (TACE), TNFRs and TNF-&#945; are released in their soluble form. Thus, fragments of extracellular domains of both TNF-&#945; receptors (type I and II), which can be released from the cell membrane and quantified in their soluble form (TNFR I and TNFR II) in urine and plasma, they have been described as biological activity regulators of this cytokine<sup>32</sup>.</p>
      <p>In physiological concentrations, TNFRs can act as a reservoir for slow release, thus increasing the half life of this cytokine<sup>23,33</sup>. When present in high concentrations, as in patients with severe HF (class III and IV, NYHA), TNFRs can inhibit the pathological increase of TNF- &#945; activity, thus acting as a anti-TNF-&#945;<sup>8</sup>.</p>
      <p>In 1990, Lavine et al<sup>34</sup> observed that HF patients had increased levels of this cytokine (115 &#177; 25 X 9 &#177; 3 U/mL) when compared to individuals without the disease. They also showed that the greater the increase, the greater the tendency of these patients to develop cardiac cachexia. Recent studies have shown high concentrations of TNF-&#945; in individuals with cardiac cachexia and this cytokine is also an important predictor of weight loss<sup>35</sup>.</p>
      <p>TNF-&#945; may be the main cause of a number of metabolic disorders in patients with HF, such as high metabolic rate<sup>25</sup>; decrease in blood flow to peripheral tissues and endothelial dysfunction<sup>7,36</sup>; activation of iNOS<sup>11,37</sup>; and changes in the metabolism of proteins and lipids<sup>38</sup>. In addition to their known thermogenic effect, high concentrations of these cytokines may be related to increased plasma concentrations of insulin, abnormalities in the metabolism of steroid hormones and growing hormone<sup>39</sup>, left ventricle dysfunction<sup>5</sup> and exercise intolerance<sup>3,7,40</sup>.</p>
      <p>However, little is known regarding the mechanisms responsible for inducing the increase in the production of TNF-&#945;, and thus, some hypotheses have been proposed (<xref ref-type="fig" rid="en_21f1-body3">Figure 1</xref>). It is known that activated monocytes and macrophages are the main source of TNF-&#945;<sup>23</sup>, and that an increase in the production of prostaglandin E2, observed in patients with HF, could stimulate macrophages to produce TNF-&#945;<sup>38</sup>. Previous<sup>41</sup> studies demonstrated that macrophages from the peritoneal cavity of rats with MI-induced HF increased the production of TNF-&#945;, and other pro-inflammatory cytokines (IL-1&#946; and IL-6), when stimulated with lipopolysaccharide (LPS).</p>
      <p content-type="asset">
        <fig id="en_21f1-body3">
          <graphic xlink:href="1678-4170-abc-93-06-0692-00021-gf01-en.jpg"/></fig>
      </p>
      <p>On the other hand, recent evidence suggested that in HF, TNF-&#945; changes are present regardless of the inflammatory condition and the cause of the disease, suggesting that the increase in this cytokine is associated with the presence of constraints imposed by the HF, rather than HF being the cause of this condition<sup>6,42</sup>. Thus, in HF, the mechanisms that modulate the production of TNF-&#945; are poorly understood, on the other hand, this cytokine seems to have a complex role, and it seems to be a between several regulatory systems<sup>5,38</sup>.</p>
      <p>
        <bold>Role of IL-10 in the progression of HF</bold>
      </p>
      <p>Due to the large number of studies that associated the role of pro-inflammatory cytokines to the pathogenesis and progression of HF, the possibility of using interventions that handle anti-inflammatory cytokines as an adjuvant therapy in patients with HF has been theorized. On the other hand, despite this therapeutic potential, only recently the role of IL-10 in HF has been the focus in studies<sup>14,43</sup>.</p>
      <p>Interleukin 10 (IL-10) is a homodimeric polypeptide of 17 kDa, which was initially described as a factor produced by T helper lymphocytes (type 2) with inhibitory properties in clones of T helper lymphocytes (type 1), especially in the proliferative response and the production of cytokines<sup>21</sup>. This cytokine is produced by a number of different cell types, especially inflammatory cells such as macrophages and T lymphocytes, in which it is the main inhibitor of cytokine synthesis and macrophage functional activity. It also inhibits the production both of the pro-inflammatory cytokines and the extracellular matrix metalloproteinases<sup>8,21</sup>.</p>
      <p>Its biological activity is mediated by its membrane receptor (IL-10R), which belongs to a subgroup of receptors that are similar to interferon (INF), from the Class II cytokine receptor family<sup>21,22</sup>. Thus, IL-10 can inhibit the production of several cytokines such as TNF-&#945;, IL-1&#946; and IL-6, in various cell types, and it is also self-modulated<sup>15,21</sup>. It also inhibits the generation of reactive oxygen species (intermediate) and increases the release of TNFR receptors, which may antagonize the effects of TNF-&#945;<sup>44</sup>. Furthermore, studies have shown that IL-10 production increased in inflammatory processes, such as anemia and rheumatoid arthritis, and also in HF, exerting a predominantly immunomodulatory role in such conditions<sup>15</sup>.</p>
      <p>Bolger et al<sup>45</sup> demonstrated that IL-10 inhibits the secretion of TNF-&#945; in isolated peripheral blood mononuclear cells (ex vivo) of HF patients (functional class III, NYHA). In another chronic inflammatory condition such as atherosclerosis in mice (C57BL/6J, IL-10 knockout mice), IL-10 has also been described by its protective (anti-inflammatory) properties in delaying the progression of the disease, since high levels of IL-10 were associated with a reduction in apoptosis and the expression of iNOS-1 mRNA in the endothelial cells, macrophages and T lymphocytes of these animals<sup>46</sup>.</p>
      <p>As explained above, the IL-10 acts in a predominantly anti-inflammatory and modulatory manner in the inflammatory response, a condition that seems to be even more evident in chronic inflammatory diseases, especially in those in which TNF-&#945; seems to act in a significant manner (ex.: rheumatoid arthritis, multiple sclerosis, inflammatory disease of the digestive tract, HF, among others)<sup>45,47,48</sup>. Accordingly, the study of Gullestand et al<sup>43</sup> demonstrated that the intravenous infusion of immunoglobulin, a therapy used in immune system-mediated diseases, such as Kawasaki syndrome, dermatomyositis and multiple sclerosisincreased IL-10 levels in patients with HF (dilated cardiomyopathy and ischemic myocardial disease). Moreover, this increase showed a positive correlation with the improvement in the ejection fraction of the left ventricle in patients with HF, as well as in animals with MI-induced HF. The production of IL-10 by TNF-&#945; (IL-10/TNF-&#945; rate) in the left ventricle proved to be a more accurate indicator of the degree of ventricular dysfunction in this condition<sup>48</sup>.</p>
      <p>Recently, the study of Yu et al<sup>49</sup> showed that peripheral manifestations of MI-induced HF in rats can be alleviated by reducing the intensity of the inflammatory/immune response in the brain. In these animals, the change in balance of pro and anti-inflammatory cytokines induced by the administration of an adenoviral vector encoding the gene for human IL-10, produced "beneficial" effects in the severity of HF, such as an improvement in left ventricular function and a decrease in plasma norepinephrine levels, and less prominence in the remodeling of the right ventricle and pulmonary vascular congestion. Another study, which administered rhIL-10 in vivo showed the same effect<sup>45</sup>. In addition, Yamaoka et al<sup>15</sup> demonstrated that mononuclear leukocytes collected from patients with HF (functional class II-IV, NYHA) had a greater number of IL-10 receptors in their cell membranes.</p>
      <p>Altogether, these studies suggest an important role of IL-10 in the pathophysiology of HF, mainly due to its modulating effect in the synthesis and secretion of TNF-&#945;. Thus, this cytokine is gaining a prominent role as a therapeutic option. Moreover, the IL-10/TNF-&#945; rate may have a cumulative role in the evaluation of the deterioration and progression of the HF. On the other hand, more studies are needed for the understanding of the molecular mechanisms that modulate the events above described.</p>
      <p>
        <bold>Effect of aerobic training on pro-inflammatory cytokines in HF</bold>
      </p>
      <p>It is now well established that physical training is directly related to the functional improvement of quantitative physical capacity, such as in VO<sub>2peak</sub>, in endothelial function and consequently in the quality of life of patients with HF<sup>11,50-52</sup>. Other variables associated with a worse prognosis, such as an improvement in sympathetic and neuro-hormonal activity and peripheral hypoxia, have also been reported as being positively modulated by physical training<sup>53</sup>. Another aspect to highlight is its direct effect on the reduction in submaximal heart rate (during exercise) and at rest<sup>50</sup>. Consequently, physical training has been recommended by medical guidelines<sup>1,18</sup> as a component in therapeutic rehabilitation programs for patients with controlled HF.</p>
      <p>Besides the benefits already mentioned, recently Adamapoulus et al<sup>54</sup> showed a reduction in plasma concentration of peripheral inflammatory markers (soluble cell adhesion molecule-1, soluble vascular cell molecule-1 and macrophage chemoattractant protein-1) after 12 weeks of aerobic training on a cycle ergometer (70-80% HR<sub>max</sub>), five times a week for one hour per day in patients with moderate to severe HF (NYHA, functional class II - III). Thus, it suggests a correlation between improvement in exercise tolerance and the attenuation of the inflammatory process due to a possible reversal of the deleterious effects caused by the endothelial dysfunction that is present in HF. Accordingly, Batista et al<sup>20</sup> demonstrated the reversal of some inflammatory parameters in peritoneal macrophages and mesenteric lymph nodes in rats with MI-induced HF a program of moderate aerobic training (running on a treadmill) with duration of 10 weeks, reaching values close to those found in control groups. However, the evidence of a significant correlation cannot establish a cause and effect relationship, and other mechanisms have been proposed to explain the "beneficial" effects mediated by physical training in individuals with HF.</p>
      <p>A reduction in plasma concentration of TNF-&#945;, IL-6 and their receptors in soluble form have also been demonstrated in individuals with HF undergoing an aerobic training program<sup>55</sup>, suggesting a reduction in the chronic inflammatory condition, mediated by a regulation in peripheral inflammatory response<sup>56,57</sup>. However, despite the marked restorative and/or anti-inflammatory effect of exercise in these conditions, little is known about the possible mechanisms by which aerobic training can modulate this process<sup>57</sup>.</p>
      <p>Following this line of reasoning, Gielen et al<sup>58</sup> published the first study that showed an increase in the local expression of pro-inflammatory cytokines in biopsy samples from skeletal muscle in subjects with HF. Moreover, this increase was not shown when the parameter measured was the plasma concentration of these cytokines, and thus it has been speculated that the local inflammation preceded the detected plasma changes. In the same study, the aerobic training in an ergometric treadmill at 70% VO<sub>2peak</sub>, for six months, reduced this increased local expression because it showed that this reduction was associated with a reduction in the expression of the iNOS gene and the intracellular accumulation of NO, therefore suggesting that physical training should be used not only as a form of intervention aiming at improving physical capacity (affected or not by HF), but also as a therapeutic strategy with local anti-inflammatory purposes.</p>
      <p>More recently, the same group of authors showed that the anti-inflammatory effect induced by aerobic training in the expression and production of cytokines (TNF-&#945;, IL-1&#946;, IL-6) and iONS, which were associated with an improvement in the maximum activity of cytochrome c oxidase enzyme (COX) and in VO<sub>2peak</sub>, suggests that the improvement in the inflammatory parameters was based on an improvement in skeletal muscle oxidative metabolism in patients with HF<sup>11</sup>.</p>
      <p>A reduction in plasma concentration of TNF-&#945;, IL-6 and their receptors in soluble form have also been demonstrated in individuals with HF undergoing an aerobic training program<sup>55</sup>, suggesting a reduction in chronic inflammation, mediated by a regulation in the peripheral inflammatory response<sup>54,55</sup>. Similarly, a program of four months of physical training with aerobic exercises on a cycle ergometer (90% of anaerobic threshold-I), three times a week for 20 minutes, along with resistance exercises (50% of repetition maximum and nine exercises per session) for 30 minutes, showed a reduction in the concentration of TNFRs I and II in patients with HF, that suggests possible effects of the simultaneous use of aerobic exercises and resistance exercises on the attenuation of inflammation<sup>56</sup>.</p>
      <p>Therefore, recently accumulated scientific evidence suggests that inflammatory mediators such as pro-inflammatory cytokines, play an important role both in the pathogenesis and the development of the HF syndrome. Thus, besides exerting a positive effect on cardiocirculatory variables, which is well established in the literature, moderate physical training programs lasting from three to six months, with three to five one-hour sessions per week, act as an important positive immunomodulator, thus, albeit partially, reverting the inflammatory changes that arise from HF and reinforcing their role as a non-pharmacological intervention.</p>
      <p>
        <bold>Role of physical training as an anti-inflammatory strategy</bold>
      </p>
      <p>In recent years, several studies have suggested that an acute session of physical exercise has anti-inflammatory effects, especially immediately after the exercise; the main cytokine involved in this modulation is IL-6<sup>59,60</sup>. This anti-inflammatory effect is characterized by a subsequent increase in plasma levels of the cytokines IL-10, ILra and the soluble TNF receptors I and II, induced by the IL-6 after a session of physical exercise<sup>60</sup>. Moreover, this effect is more evident in some clinical pictures, such as atherosclerosis, type II diabetes, obesity and HF, especially those characterized by chronic low grade inflammation, a condition that is characterized by two or three-fold systemic increase in the levels of pro-inflammatory cytokines and C-reactive protein<sup>61</sup> (<xref ref-type="fig" rid="en_21f2-body3">Figure 2</xref>).</p>
      <p content-type="asset">
        <fig id="en_21f2-body3">
          <graphic xlink:href="1678-4170-abc-93-06-0692-00021-gf02-en.jpg"/></fig>
      </p>
      <p>Furthermore, the profile of cytokine production that occurs during and immediately after exercise is dependent on many factors such as population (sedentary, presence or absence of disease, etc.); intensity or duration of exercise; availability of glucose; and time of sample collection<sup>62</sup>.</p>
      <p>Therefore, the proposed hypothesis is that the regular practice of physical exercise, organized as a training program, has an anti-inflammatory effect induced by acute multiple sessions, which leads to protection against chronic inflammatory conditions, especially by reducing the levels of pro-inflammatory cytokines and C-reactive protein<sup>60,63</sup>. Despite the obvious correlation, little information has been produced until now regarding the possible mechanisms that explain the cause-effect relationship between physical training and the reduction in these markers levels<sup>59</sup>. Also, the origin of this systemic change is not well characterized. However, it has been proposed that white adipose tissue<sup>60</sup> and peripheral blood mononuclear cells (especially lymphocytes) may be the main source of cytokines<sup>59,63</sup>.</p>
      <p>To evaluate this possible anti-inflammatory effect, Starkie et al<sup>64</sup> showed a reduction in the levels of TNF-&#945; induced by the experimental model in a low grade systemic inflammation experimental model, which was induced by the intravenous administration of endotoxin (Escherichia coli) to healthy subjects, three hours after a session of aerobic exercise on a cycle ergometer (75% VO<sub>2peak</sub>)&#945;. The same suppressive effect induced by physical exercise was also demonstrated in knockout mice for TNF-&#945; receptor type I and II, in restoring the increased levels of TNF-&#945;<sup>65</sup>. However, the possible mechanisms that modulate this "beneficial" effect have not been established.</p>
      <p>
        <bold>Possible mechanisms involved in the anti-inflammatory response after exercise</bold>
      </p>
      <p>Although the importance of pro-inflammatory mediators in the pathogenesis of HF was confirmed in the last few years, only recently it was noted that this was not accompanied by a corresponding increase in anti-inflammatory cytokines such as IL-10 and in transforming growth factor (TGF), resulting in an imbalance in the levels of cytokines (pro vs. anti-inflammatory).</p>
      <p>The pharmacological treatment that is conventionally used in HF with an impact on mortality (e.g. &#946;-blockers, angiotensin-converting enzyme inhibitors, and spironolactone) has shown slight effects in the reduction of inflammatory markers in these patients, and thus, an immunomodulatory therapy has been proposed and tested in combination with the conventional treatment as an adjuvant option<sup>66</sup>. The adjuvant therapy (eg, pentoxifylline, intravenous immunoglobulin, thalidomine, infliximab and statins) has shown promising results in small studies, but only in relation to outcomes of minor clinical relevance, such as an improvement in the biochemical profile<sup>66</sup>. Traditionally, patients with HF are excluded from studies in which the effects of statins are tested in clinical events. However, a recent study<sup>67</sup> evaluated the effect of statin (rosuvastatin) in patients over 60 years of age with moderate to severe systolic heart failure. In the study, the use of 10mg/day of rosuvastatin had a statistically significant effect in reducing the levels of LDL-cholesterol and inflammatory markers such as C-reactive protein.</p>
      <p>In this aspect, as described above, the use of physical training as an adjuvant therapy, besides restoring cardiovascular function changes that occurred because of the HF (which does not seem to occur in the therapeutic adjuvants mentioned above), proved to be an important immunomodulatory agent. On the other hand, despite increasing evidence that demonstrates the importance of IL-10, mainly due to its anti-inflammatory action, few studies have evaluated the possible effects of physical training in modulating the local production of IL-10, which has an important role in the pro/anti-inflammatory balance, especially in conditions in which there is an imbalance in this relationship.</p>
      <p>Therefore, the proposed hypothesis is that the regular practice of physical exercise, organized as a training program, has an anti-inflammatory effect induced by acute multiple sessions, which leads to protection against chronic inflammatory conditions, especially by reducing the levels of pro-inflammatory cytokines and C-reactive protein<sup>60,63</sup>. However, the possible mechanisms modulating this "beneficial" effect are not established and could be related both to an improvement in conditional physical capacity and a direct anti-inflammatory effect.</p>
      <p>As already described, IL-10 modulates inflammatory processes by eliminating the production of pro-inflammatory cytokines, especially TNF-&#945;, which is transcriptionally modulated by NF-&#186;B. Furthermore, a recent study showed that in rats, the aerobic training on an ergometric treadmill increases the activation of this system, notably by reducing the levels of I&#186;B&#945; (NF-&#186;B system inhibitory protein) and increasing the phosphorylation of IKK (an enzyme that degrades the I&#154;B protein complex)<sup>68</sup>. It is also noteworthy that, despite evidence showing that IL-10 inhibits a number of changes mediated by TNF-&#945;, especially those involving the activation of NF-&#186;B, and that aerobic training increases the activation of this system, none of these studies evaluated the effect of training on a condition in which NF-&#186;B is activated, such as HF. Moreover, in patients with diabetes type II, a program of aerobic training on an ergometric bicycle (70% VO<sub>2peak</sub>, four times a week for eight weeks) showed an increase in protein levels of I&#186;B&#945; and &#946; in both groups (diabetic and control of the same age) which was followed by a reduction in protein levels of TNF-&#945;<sup>69</sup>. Therefore, the possible mechanisms concerning the effect of physical training in HF, which modulates the production of TNF-&#945; by increasing IL-10, is shown in <xref ref-type="fig" rid="en_21f3-body3">Figure 3</xref>.</p>
      <p content-type="asset">
        <fig id="en_21f3-body3">
          <graphic xlink:href="1678-4170-abc-93-06-0692-00021-gf03-en.jpg"/></fig>
      </p>
      <p>
        <bold>Final considerations</bold>
      </p>
      <p>Given the above, data from the literature support the anti-inflammatory hypothesis. Notably, IL-10 protein appears to be affected by physical training (mainly aerobic) and may act as an important "trigger" in the reduction and/or modulation of the inflammatory response in HF. Also, in addition to an increase in the local production of IL-10, induced by physical training, this effect could have a systemic impact, reducing or even preventing the increase in plasma levels of pro-inflammatory cytokines, a condition that is related to increased severity of the disease, in HF. Studies that evaluate the effect of controlled physical training in relevant clinical outcomes, such as mortality in HF patients, are needed to incorporate this treatment modality into clinical practice.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of doctoral submitted by Miguel Luiz Batista J&#250;nior, from Departamento de Biologia Celular e do Desenvolvimento do Instituto de Ci&#234;ncias Biom&#233;dicas - USP.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
